











This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
• This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
• A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
• This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
• The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
• When referring to this work, full bibliographic details including the author, title, 




The role of tetrahydrobiopterin in 








Doctor of Philosophy 










I solemnly declare that the work in this thesis is entirely my own, except where 
otherwise stated and referenced. This work has not been previously been 




































































A scholar ther was of Maidenhead also, 
That un-to logik hadde longe y-go. 
As lene was his hors as was a rake, 
And he nas nat right fat, I undertake; 
But loked holwe, and ther-to soberly. 
Ful thredbar was his overest courtepy; 
For he had geten him yet no benefyce, 
Ne was so worldly for to have offyce. 
For him was lever have at his beddes heed 
Twenty bokes, clad in black or reed, 
Of Aristotle and his philosophye, 
Than robes riche, or fithele, or gaye sautrye. 
But al be that he was a philosophre,  
Yet hadde he but littel gold in cofre. 
But al that he mighte of his freendes hente, 
On bokes and on lerninge he it spente, 
And bisily gan for the soules preye 
Of hem that yaf him wher-with to scoleye. 
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Nitric oxide synthase (NOS) catalyses the production of nitric oxide (NO). A 
cytochrome P450-like oxygenase, it uses two monooxygenation steps to 
convert L-arginine (L-arg) first to Nω-hydroxy-L-arginine (NOHA), a stable 
intermediate, and then to L-citrulline and NO. Mammalian NOSs are 
homodimeric enzymes. Each monomer is composed of an oxygenase domain 
(containing the L-arg binding site, a heme ligated by a cysteine thiolate, and a 
tetrahydrobiopterin (H4B)) and a reductase domain (binding NADPH, FAD, 
and FMN). NOS substrates are O2, L-arg, and NADPH. NADPH is the source 
of electrons required for oxygen activation. H4B is a vital cofactor that aids 
dimerisation and acts as a reducing/oxidising agent. Controversy still exists as 
to the final oxygenating species in the NOS mechanism, but the general 
reaction scheme is known. The ferric heme is reduced to the ferrous state by an 
electron from the reductase domain. Then oxygen binds to form the oxy-ferrous 
species. Then H4B donates an electron to form a peroxy-ferric species. It is 
likely this then forms a compound 1 (Fe(IV)+.=O) species that is the final 
oxygenating species.  
   This thesis probes the mechanism of NOS to further define the mechanistic 
intermediates involved. The role of H4B in NO synthesis has been probed in 
both normal turnover conditions and special case reactions. 
   To elucidate this mechanism further a mutant with a residue capable of 
stabilising the activated oxygen species was created, G586S, where glycine 586 
of nNOS was replaced with a serine. This serine was within hydrogen bonding 
distance of the oxy-heme. A stabilised intermediate was observed by stopped 
flow reaction in the presence of H4B, but not aH4B (an inactive pterin 
analogue). Here single turnover  reactions, each following either the reaction of 
L-arg to NOHA or NOHA to citrulline, were performed on the mutant using an 
external source of electrons. The reaction products were observed by HPLC. 
The mutant appears capable of the conversion of NOHA to citrulline, but not 
L-arg to NOHA. The WT enzyme appears capable of both. The intermediate is 
observed with either L-arg or NOHA bound, suggesting both reactions proceed 
via the same active oxygenating species. The inability of the mutant to catalyse 
the conversion of L-arg to NOHA may be due to protonation of the substrate 
hindering reaction such that the active oxygenating species decays before 
reaction can occur. This mutation, in allowing separation of the two 
monooxygenation steps, deserves further study. 
   H4B binds at the dimer interface of NOS. Here the π-systems of the pterins 
are only 13Ǻ apart. This is within allowed distances for efficient electron 
transfer. Electron transfer between hemes, via the pterins, would allow a route 
for the breakdown of a dead end, ferrous-NO, species. Stopped flow 
monitoring of the decay of the ferrous-heme NO complex with nNOSoxy 
dimers with varying proportions of the hemes in the ferrous heme-NO complex  
showed no electron transfer between hemes of the dimer. The rate of decay of 
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the ferrous heme-NO complex in oxygenated buffer is 0.12 s-1 for all 
conditions tested here. 
   H4B-deficiency leads to several diseases. H4B makes a poor drug due to 
instability and cost, the search for druggable analogues of it is ongoing. H4B 
analogues blocked at the 6,7-positions in the dihydropterine-form have been 
screened here for catalytic activity. Several have shown comparable ability to 
catalyse NO production in vitro. Structure function analysis of these analogues 
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Standard amino acid abbreviations are used throughout, e.g. Tryptophan is Trp or W. 
 
Mutations are referred to by single letter amino acid codes and location within the 
protein. Thus a mutation the glycine at position 586 in the nNOS protein to a serine 
would be called G586S. 
 
 
A    Absorbance 
Al    Autoinhibitory Loop 
aH4B    4-amino-tetrahydrobiopterin 
ATP    Adenosine triphosphate 
CaM    Calmodulin 
cGMP    Cyclic guanosine monophosphate 
cNOS    Constitutive nitric oxide synthase 
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EGTA    Ethyleneglycoltetraacetic acid 
eNOS    Endothelial nitric oxide synthase 
EPR    Electron paramagnetic resonance 
FAD    Flavin adenine dinucleotide 
FMN    Flavin mononucleotide 
FNR    Ferredoxin−NADP+ reductase 
FPLC    Fast protein liquid chromatography 
sGC    Soluble guanylate cyclase 
GSH    Glutathione 
GTP    Guanosine tripohosphate 
H4B    Tetrahydrobiopterin 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC    High pressure liquid chromatography 
iNOS    Inducible nitric oxide synthase 
IPTG    Isopropyl-β-D-thiogalactoside 
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KPi    Potassium phosphate buffer 
L-arg    L-Arginine 
LB    Luria/Bertani  
MES    2-(N-morpholino)ethanesulfonic acid 
MW    Molecular weight 
NADPH   Nicotinamide adenine dinucleotide phosphate 
NMR    Nuclear magnetic resonance 
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nNOS    Neuronal nitric oxide synthase 
NO    Nitric oxide 
NOHA    N-hydroxy-L-arginine 
NOS    Nitric oxide synthase 
NOSoxy   Nitric oxide synthase oxygenase domain 
NOSrd    Nitric oxide synthase reductase domain 
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PMSF    Phenylmethylsulfonyl fluoride 
SOC    Super optimal catabolite 
SOD    Superoxide dismutase 
SDS    Sodium dodecyl sulphate 
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1.1 Nitric oxide  
 
Nitric oxide (NO) is a diatomic radical molecule. NO was, prior to the discovery of its 
place in physiology, considered a gaseous pollutant. NO is, however, now known as a 
signalling molecule that is involved in a plethora of physiological processes and vital to 
the complexity of life (1, and references therein). 
  Furchgott, Ignarro and Murad were awarded the Nobel Prize in Physiology or Medicine 
in 1998 for their work in identifying the role of NO as a relaxing agent of blood vessels 
(2, 3). A previously observed but uncharacterized Endothelial Relaxation Factor (EDRF) 
was known to relax smooth muscle, particularly in blood vessels. Clues to the identity of 
the EDRF came from the inhibition of EDRF action by superoxide anions generated by 
methylene blue. However a key finding was that acidified rather than neutral sodium 
nitrite produced transient relaxations of the aorta. NO gas was then found to produce 
similar results. Then Guanylyl-cyclase activation by EDRF was found to be heme 
dependent, a further link to NO, a fine binder of hemes (4). 
   Now NO is clearly established as playing a vital role in life. Its physiological roles range 
from that of being a cytotoxic agent during immune response acting in a cell destructive 
way, to a neurotransmitter diffusing between synapses to reinforce signal transmission.  It 
is also involved in nitrosylation of proteins, modulating their activity (5). Its ability to 
fulfill these roles simultaneously is due to its chemical properties. As a small molecule it 
is able to diffuse rapidly across hundreds of microns. As an uncharged molecule it is able 
diffuse across lipid membranes and so enter cells. As a radical molecule it is unstable and 
reactive. It readily forms complexes with transition metals as well as reacting with protein 
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residues. All of these chemical properties allow NO to play so many varied roles 
physiological roles. These roles will be discussed further in relation to the biological 
process of NO formation. 
 
As a diatomic signalling molecule it was a great novelty and research into its production 
and roles began at once and continued and continues at great pace. Papers are published in 




Nitrosylation is a post-translational modification of proteins directly analogous to 
phosphorylation. Nitrosylation is able to alter the activity of a protein dramatically. The 
most well known nitrosylation, although not the only possible, is S-nitrosylation, 
mechanism shown in Figure 1.1 (6). 
 
Figure 1.1- This is the generally accepted route for S-nitrosylation. Here R is a cysteine 
residue to be nitrosylated. To achieve nitrosylation the three distinct steps shown above 
occur. 
 
S-nitrosylation is the reaction of reactive NO-products with certain cysteine residues in a 
protein. This can occur randomly, but there are also enzymes which catalyse the reaction 
specifically. It has also been suggested that S-nitrosylated proteins may act as carriers of 
NO to prolong its activity and preserve it from the reactive species found physiologically 
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(7). For example, red blood cells release S-nitrosothiols under low oxygen concentration 
leading to blood vessel relaxation presumably by NO release from the nitrosothiols (8). 
Targets of this modification can be proteins with essential roles such as hemoglobin and 
serum albumin. Misplaced protein nitrosylation and denitrosylation have been associated 
with pathologies such as myocardial ischemia, atherosclerosis, inflammation, and cancer 
(9). Clearly these are topics of research interest and therefore NO remains at the forefront 
of medical science. 
1.3 Interaction with Guanylyl Cyclase 
 
The most important enzyme targeted by NO is soluble Guanylyl Cyclase (sGC), the 
enzyme that catalyses the conversion of guanosine triphosphate (GTP) to cyclic guanosine 
monophosphate (cGMP), Figure 1.2. 
 


































                  
Figure 1.3 - Showing the role NO plays linking Ca2+ concentrations to final outcomes.  
The NO produced by constitutive NOSs in response to increased Ca2+ levels may affect 
intracellular events, or as shown here diffuse between cells. NO activates sGC and 
promotes production of cGMP. cGMP activates protein kinases, phosphodiesterases and 
ion channels giving a range of physiological responses. (Adapted from Papale, 2008) 
 
sGC is, in fact, the only known receptor of NO.  By NO binding to the heme of sGC a 
proximal histidine ligand is dissociated and the protein activated. NO binding increases 
the activity of the enzyme by 300 times (10). This interaction of NO with sGC derives its 
importance from the huge number of processes in which cGMP has a role. It acts in 
smooth muscle relaxation, regulation of synaptic transmission and platelet aggregation 
inhibition. These, and other processes, are controlled through the action of cGMP-
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dependent enzymes, such as protein kinases, phosphodiesterases and ion channels. NO 
production is sensitive to the increase of calcium concentration as will be discussed later. 
Therefore NO links calcium concentration and the production of cGMP. Figure 1.3 shows 
the pathway of NO and cGMP (11,12). 
 
1.4 Chemical properties of NO  
 
Some of the most interesting features of NO are due to its radical nature. The unpaired 








Figure 1.4- Molecular-orbital energy-level diagram for nitric oxide. 
 
 The unpaired electron is positioned in an antibonding orbital and is shielded from the 
nucleus by the inner electrons, allowing it to be easily lost and giving rise to the formation 
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of NO+.  When complexed with metals, NO can be considered to be either an electron 
donor or acceptor, binding as either NO+ (nitrosonium cation) in a linear geometry or as 
NO- (nitroxyl anion) in a bent geometry, both via the nitrogen. The relatively small 
difference in electronegativity between oxygen and nitrogen gives the bond a very limited 
polar character, with the electrons being more probably found around the oxygen atom. 
NO can be described as an almost non-polar molecule, allowing it to act as an efficient 
messenger molecule across the lipid membrane of cells. Being a radical molecule NO is 
unstable, giving it a limited diffusion range and so localizing the effects of NO 
production. 
  What is fascinating is that when in solution NO, unlike other nitrogen and carbon 
radicals, does not dimerise but remains in the active monomer form (13).  
    As already said the most significant biological role of NO is in the reaction with the 
heme group of sGC. How then does NO coordinate with a heme iron? 
  Unlike other ligands (such as CO and O2) NO will bind to hemes in either the ferric or 
ferrous states (as will cyanide and water). The binding of NO to ferric heme is rapidly 
reversible. It can be considered in either of two states; FeIII-NO or FeII-NO+ (14). 
  NO is a superb ligand for the ferrous heme. This is because of the donation of electrons 
from the NO to the heme iron and the overlap of the iron d-orbitals and the antibonding 
orbitals of NO. The ferrous heme-NO complex is such a tightly bound complex that, as 





1.5 Biological electron transfer 
 
The transfer of electrons underpins all chemical reactions (15). Animals must extract 
energy stored in chemical bonds in a useful form. This is achieved by a process of 
gradual oxidation. Oxidation here does not necessarily mean the direct reaction of a 
molecule with oxygen but the loss of electrons by transfer, often catalysed by proteins. In 
this thesis protein mediated electron transfer will prove key to the understanding of NOS 
mechanism. There is a long electron transfer distance to be made in the reductase domain 
of NOS, and the mechanism of reaction at the active site relies on electron transfer from 
several sources. To understand this the general theory of electron transfer must be 
discussed before applying it to biological systems. 
 The rate of the electron transfer depends upon ∆G*, the change in energy in the system 
under standard conditions, according to the following equation, 
 
k′ = k′0 exp [- ∆G
*/ kT]           (Eqn. 1)                
 
where k′ is the observed electron transfer rate, k′0 is the rate of electron transfer when 
∆G* is zero, T is the temperature in Kelvin and k is the Boltzmann constant.  Generally 
the rate of electron transfer will increase with ∆G and temperature. However there is an 
optimal ∆G at which electron transfer is ‘activationless’ (16).  
  From orbital theory we see that an electron transfer reaction in a biological system must 
involve movement of an electron from a donor orbital to an acceptor orbital. This 
requires the electron to ‘tunnel’ through the intervening medium, which is of higher 
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energy, and the extent of the tunnelling necessary is dependent upon the amount of 
overlap of the electronic wavefunctions of the orbitals involved. The greater the overlap 
then the faster the rate of electron transfer. It is known from quantum mechanical theory 
that the energy of electronic wavefunctions decreases exponentially with distance, and 
therefore it follows that the rate of electron transfer will also decrease exponentially with 
distance. The strength of the electronic coupling between the donor and acceptor orbitals 
is given by HAB, the tunnelling matrix element. The value of k′0 is directly proportional to 




AB exp [ -½β (d – d




AB is the electronic coupling at close contact (d
0), and β is the rate of decay of coupling 
(in Å-1) over distance d. In a vacuum the value of β is typically about 2.8 Å-1, implying 
that electron transfer can only occur over relatively short distances (17). Long distance 
electron transfer in biological systems requires that the value of β for the intervening 
medium be smaller than that observed in vacuo, and a value of 1.4 Å-1 has been suggested 
for a protein medium (18). Practically, this value means that a 10-fold decrease in the rate 
of electron transfer is observed with an increase in distance between the redox centres of 
1.7 Å. This general value of β for proteins means that the intervening medium can be 
thought of as a homogeneous ‘organic glass’. Although this approximation may be 
acceptable for systems optimised for electron transfer, reactions with a more 
heterogeneous intervening medium require more careful consideration. The explanation 
for such situations involves tunnelling pathways through covalent bonds, hydrogen 
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bonds, and direct through-space jumps (19). This complicates consideration of electron 
transfer in biological systems, where redox centres are normally surrounded by a protein 
medium. In such cases many differing pathways may be possible routes for electron 
movement and it is possible that stabilisation of electronic wavefunctions may be greatest 
in a longer pathway, and electron transfer may therefore occur at a greater rate than it 
would via the shortest pathway.  
 
1.6 Biological NO synthesis 
 
NO is produced biologically by means of the enzyme nitric oxide synthase (NOS) shown 
in Figure 1.5 (20). This was the first example of an enzymatic hydroxylation of the L-
Arginine (L-Arg) guanidinium group (21). 
 
 
Figure 1.5 - Enzyme catalyzed production of NO showing the two monooxygenation 
steps performed by nitric oxide synthase.  
 
L-Arginine, once bound into the catalytic site of NOS, can undergo a first oxidation, that, 
with the consumption of molecular oxygen and 2 electrons, leads to the formation of  Nω-
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Hydroxy-L-Arginine (NOHA) and water. This reaction intermediate stays bound to the 
catalytic site and undergoes a second monooxygenation, performed with the consumption 
of 1 electron equivalent and 1 molecule of oxygen. This leads to the production of water, 
L-citrulline and nitric oxide. Of course each step can be further broken down into several 
stages. This more complex reaction scheme is still hotly debated amongst researchers and 
will be discussed further in the section on the catalytic cycle of nitric oxide synthases. 
  
1.7 NO from Nitrate and Nitrite 
 
There is a second path for NO production that is only now being closely studied (22, 23). 
Nitrite (NO2
-) and nitrate (NO3
-) are the end products of NO oxidation in the body. They 
are also taken in from the diet. While the NOS derived NO production requires oxygen, 
NO from the reduction of nitrite does not require oxygen, and is in fact favoured by 
anoxia. It has been found that as levels of oxygen fall in the blood there is an increase in 
NO production from nitrite and nitrate (24). Mammals lack specific nitrate and nitrite 
reductases, but several routes have been suggested. Nitrate must be reduced to nitrite 
first, it has been suggested that commensal bacteria perform this conversion, and then the 
stable nitrite must be converted to NO.  There are several pathways that can achieve this: 
involving haemoglobin (25), myoglobin (26), xanthine oxidoreductase (27), ascorbate 
(28), polyphenols (29) and protons (30). However none of these pathways produces NO 
at a satisfactory rate under physiological conditions and so the route of NO from nitrite 
remains an open question. 
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  Under conditions of acidosis or hypoxia the rates of nitrite reduction increase greatly 
and NO is produced at physiologically relevant rates. This makes physiological sense as 
under hypoxia the vasodilator effects of NO would be beneficial to increase blood flow to 
the aeschemic area. The use of nitrite as a therapeutic agent in the case of stroke or 
anoxia may soon become more common. A truly effective treatment for transient 
aeschaemic attacks would be aided if a specific and efficient pathway of nitrite reduction 
was elucidated. 
 
1.8 Nitric Oxide Synthase   
 
The group of enzymes that specifically produce nitric oxide in eukaryotes and in some 
prokaryotes are called Nitric Oxide Synthases (31). The mammalian NOSs are dimeric 
proteins in which each subunit is made of two domains, with a specific connecting region 
between the two that binds calmodulin, Figure 1.6. 
 
Figure  1.6  - Modular composition of the different NOS isoforms, showing their overall 
structural similarity though with extensions and inserts leading to isoform speciality. An 
autoinhibitory loop present in the FMN domain of eNOS and nNOS confers strict control 
of catalysis to CaM binding. 
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The N-terminal domain is called the oxygenase or heme domain and binds the cysteine-
thiol ligated heme, the substrate L-Arginine, the cofactor (6R)-5,6,7,8-
Tetrahydrobiopterin  (H4B) and forms the active site of the enzyme. The C-terminal 
portion is called the reductase domain and has the function of providing electrons to the 
heme domain derived from NADPH and transferred to the heme by sequential reduction 
of FAD and FMN. The connecting region is a flexible domain of approximately 20 amino 
acid residues capable of binding the small protein calmodulin (CaM) (32). This binding of 
CaM is possible only when CaM has Ca2+ bound to it. The CaM then binds primarily to 
an alpha-helix linking the reductase and oxygenase domains. The binding of CaM is 
thought to introduce a degree of motion within the reductase domain allowing the passage 
of electrons from one domain to the other, Figure 1.7 shows the effect of CaM on electron 
transfer in the dimer (33). The reductase domain is structurally similar to cytochrome 
P450 reductases, leading to another interesting link with these mono-oxygenating 
cytochromes to be further outlined later. In nNOS there is an N-terminal region which 
forms a PDZ domain. This region interacts with other proteins or intracellular structures 
in the organization of signal transduction complexes.  Specifically the PDZ domain binds 
to PSD (Post Synaptic Density protein) and targets nNOS to synaptic sites in the brain and 
skeletal muscle, mediating the membrane association of nNOS in neurons (34). 
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Figure 1.7 - Showing path of electrons through the NOS dimer. 1 is the transfer of a 
hydride from NADPH to FAD. 2 is the transfer of an electron  from FAD to FMN. 3 is the 
final electron transfer, from FMN to heme. Note that electrons derived from one subunit 
are passed to the oxygenase domain of the other subunit where NO synthesis occurs. This 
passage of electrons only occurs when CaM is bound. 
 
    All NOSs are functional homodimers. The dimer is formed by a large interface 
involving the heme domains of each monomer, resulting in a quasi-globular enzyme. 
Bacterial NOSs are equivalent to the oxygenase domain of mammalian NOSs, lacking 
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some of the complex control regions, but most importantly the reductase domain and 
therefore requiring an external source of electrons. The dimer of the mammalian NOSs is 
supported through interactions involving the H4B. Each subunit interacts with the H4B and 
protein expressed without H4B exists mainly in the monomer (31). Also supporting the 
dimer is a Zn2+ ion which binds to two cysteines from each subunit, though mutational 
studies have shown it not to be necessary or sufficient for dimerisation.  
  In animals three distinct isoforms of NOSs have been identified with a sequence identity 
of 50 to 60% between them. These are neuronal NOS (nNOS), inducible NOS (iNOS) and 
endothelial NOS (eNOS), or, respectively, NOS I, II and III (though these terms are 
rapidly falling into disuse as confusing, and not a moment too soon). The three isoforms 
can be divided in two other groups; nNOS and eNOS are the two constitutively produced 
enzymes whose activity is regulated by the binding of CaM. In the other group, iNOS has 
such a high affinity for CaM that CaM will bind even without the presence Ca2+. It binds 
irreversibly. The inducible form is therefore primarily regulated at the level of its 
expression, as once produced it will bind CaM and remain active until the protein is 
dismantled. 
  The length of the polypeptide chains of the two main domains are quite similar within 
the mammalian NOS isoforms, with the heme domain of about 500 residues and the 
reductase domain of about 700 (from residue 221 to 724 and from 743 to 1429 in nNOS 
respectively). The overall mass of a neuronal NOS dimer is consequently of about 160 
kDa.  The X-ray crystal structures of the isolated heme domains are available for all 
isoforms in a number of conditions (e.g. binding substrates or other ligands into the 
catalytic site) and for many bacterial NOSs (133, 134, 135, though weekly searches of the 
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protein database reveal more structures). The structure of the isolated neuronal NOS 
reductase domain has also been determined (33). On the other hand the structure of an 
entire mammalian NOS enzyme has not been achieved yet, due to the large size of the 
protein and the flexibility of portions of it. 
 
1.9 Reductase domain 
 
The NOS reductase domain (Figure 1.8 shows the structure of the reductase domain) is 
the source of the electrons required for catalysis. It is composed of two subdomains; one 
binding FMN, and one binding FAD and NADPH. There is a cleft in the FAD/NADPH 
subdomain that accommodates the FMN subdomain, with the two subdomains connected 
by a flexible linker region. As we shall see flexibility is key to the functioning of the 
reductase domain.  
 
Figure 1.8 -  Diagram of the reductase domain and subdomains. In A no CaM is bound. The 
autoinhibitory loop (dark blue) favours the close association of the FMN subdomain to the 
NADPH/FAD subdomain. Electrons may transfer to the FMN. When CaM (orange) binds, B, the 
autoinhibitory loop is rearranged and the FMN subdomain is capable of motion. It may now move 
towards the oxygenase domain and transfer an electron to the heme. Structure A may be observed 
in crystal structures (PDB 1TLL, Ref 35), B is inferred from mutagenic studies destabilizing the 






As will be discussed in the section on the heme domain there is no structural resemblance 
between the heme domain and cytochrome P450s, but a strong resemblance in 
mechanism. Here we will see there is a strong similarity between the NOS reductase 
domain and P450 reductases, to the extent that chimaeras of P450 BM3 and the NOS 
reductase domain are catalytically functional (38). There is a strong structural and 
functional relationship between the NOSrd and other diflavin reductases. The reductase 
domain is thought to have been created by a fusion of the genes that coded for proteins 
that resembled the FMN subdomain and NADPH/FAD subdomain. The FMN subdomain 
is strongly related to flavodoxin and the NADPH/FAD subdomain to ferredoxin NADP+ 
reductases. 
  The domain’s function as an electron delivery system is derived from its ability to bind 
NADPH, Figure 1.9, and the cofactors FAD and FMN, Figure 1.10, being able to shuttle 
electron through the protein (39). The flavin cofactors have stable partially reduced states 
that allow temporally controlled single electron delivery to the heme. This, as we shall see 
in the mechanism section, is vital as the delivery of two electrons at once, as would be 
derived from direct NADPH oxidation, would be futile. The route of electron delivery, 
NADPH→FAD→FMN, can be seen in Figure 1.7, and the reductase cofactors in Figures 
1.9 and 1.10. The partially reduced states of the flavins and their role in single electron 
delivery is seen in Figure 1.8.  
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Figure 1.9- NADPH structure. The source of the hydride is circled in green. 
 
 
Figure 1.10: Diagram of oxidized Flavin Mononucleotide (FMN) and Flavin Adenine 
Dinucleotide (FAD) showing the common part and the isoalloxazine ring which support 





Figure 1.11: Different oxidation states assumed by the isoalloxazine rings of FAD and 
FMN. 
 
1.9.1 Reductase domain electron transfer 
 
The electron delivery mechanism of NOSrd has been studied in depth through the use of 
truncated constructs of the subdomains and electron acceptors other than the heme domain 
(40). For example, ferricyanide is a small smolecule and therefore capable of fitting close 
to either FAD or FMN and being reduced by them. Cytchrome c, a protein of sufficient 
size to be unable to reach FAD, is capable of only accepting electron from FMN (41). 
Recall, the flow of electrons in the reductase domain is NADPH→FAD→FMN. The 
reduction rates derived are useful in informing our understanding of electron transfer. 
Also useful is the ability to follow the oxidation states of the flavins by UV/VIS.  
  The first step in electron transfer in NOSrd is the transfer of a hydride from the NADPH 
to the N5 of the bound FAD (41). To allow this transfer to occur the NADPH must move 
from a non-productive conformation to one that allows π-stacking with the isoalloxazine 





Figure 1.12 - This figure shows how NADPH may bind in a productive (a) or 
unproductive (b) orientation. The reaction is hydride transfer from NADPH (blue) to FAD 
(orange):  a) is the NADPH/FAD domain of rat nNOS (33) and b) FNR Y308S mutant 
(38, 42), showing NADPH binding in unproductive and productive conformations 
respectively. The mutation engineered on FNR, by removal of the tyrosine residue that 
controls binding in the productive mode, enhanced the stacking of the nicotinamide on 
FAD achieving a much  more ordered structure. The F1395 residue of nNOS, which 
corresponds to Y308 of FNR, must move before productive binding can occur.  
 
  The isoalloxazine ring of FAD must be stacked either with the nicotinamide ring or with 
a conserved  phenylalanine residue (F1395 in rat nNOS), and the mechanism of displacing 
each other partitions the enzyme into an active or inactive state as a consequence. This 
mechanism, as well as the secondary structure of the NADPH and FAD binding portion, 
is shared by the large family of ferredoxin−NADP+ reductase (FNR) proteins. 
   An equilibrium exists within the reductase domain between NADPH bound in the 
productive and non-productive states, Figure 1.12. This equilibrium helps to slow the 
delivery of hydrides and allows for single electron delivery to occur to the heme. Once 
bound in the productive state a hydride is transferred to the FAD, putting it in the 
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hydroquinone state, a double reduction. The FAD is held close to the FMN domain, with 
both buried within the protein. The two subdomains are held in proximity by a conserved 
electronegative patch on the FMN domain and a corresponding electropositive patch of 
residues on the FAD domain (43). Held by these salt bridges the domains bring the 
isoalloxazine rings of the flavins 5Ǻ apart and efficient electron transfer can occur. The 
domains of the flavins support electron transfer by stabilising the semiquinone forms (45). 
A conserved serine, Ser1176 in rat nNOS, stabilises the FAD semiquinone via a hydrogen 
bond to the N5, supporting single electron transfer from the double reduced FAD. Before 
a second cycle of FAD reduction can occur the proton from the hydride transfer must be 
removed from the FAD and a series of residues is thought to act a proton transfer pathway 
between FAD and solvent.  
   The FMN semiquinone is extremely stable, with Phe809 and Tyr889 in nNOS stacking 
either side of the isoalloxazine ring. The peptide backbone also forms a hydrogen bond 
with the N5 of the FMN. These interactions help to prevent the complete oxidation of 
FMN.  This facilitates the single electron transfer to the heme.  
    No full structure of the holoenzyme exists but studies have undertaken to fit all the 
structures of the isolated domains together (33). This has yielded the suggestion that the 
distance between the FMN and the heme it is to deliver electrons to may be as great as 
70Ǻ, much beyond the limit of efficient electron transfer. There must be a conformational 
change in the protein to bring the FMN a reasonable distance from the heme. 
  Passage of electrons to the heme in NOS is controlled by the binding of CaM. This is 
true of all NOS isoforms. Without CaM bound the rate of heme reduction is extremely 
slow. However the rate of flavin reduction without CaM bound is sufficient to allow 
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turnover of the enzyme, but no products are detected. This suggested that CaM controlled 
the passage of electrons to the heme. It has also been noted that CaM binding increases 
the rate of hydride and electron transfer within the reductase domain (37). 
Figure 1.13 - Structure of Calmodulin, green, binding 4 atoms of Ca2+, yellow spheres, 
while bound to the CaM binding helix of nNOS, red. Shows the CaM protein completely 






    Binding of CaM was shown to occur by the protection of a cleavage site from 
trypsinolysis in the presence of CaM (45). CaM is a small protein (less then 17 KDa) 
formed by 4 helix-loop-helix Ca2+ binding regions arranged in a double globular structure, 
Figure 1.13. In the presence of a Ca2+ atom, two helices are held in perpendicular to one 
another resulting in the exposure of hydrophobic residues, which are capable of 
interacting with recognition sites on NOS. Structures derived from x-ray crystallography 
and solution NMR show that CaM changes its shape completely on the binding of Ca2+ 
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(46). The binding of CaM to NOS has different features and effects depending on the 
isotype of NOS. The main difference being between iNOS and constitutive NOSs 
(cNOSs), eNOS and nNOS. The latter have an affinity for the CaM-Ca2+ complex in the 
range of nM, while that of iNOS is ten fold higher (Kd= 0.1 nM). iNOS is also able to bind 
CaM in the absence of Ca2+ and binds it irreversibly (47).  
     The different affinities of constitutive NOSs and inducible NOS for CaM rely not only 
on a different CaM-binding region sequence. There are at least two elements that 
differentiate the structure of the various isoforms reductase domains: these are an 
autoregulatory region which is positioned within the FMN-binding subdomain of cNOSs 
and a C-terminal extension of various lengths. Both elements exert their regulatory role 
with a mechanism that involve the interaction with CaM and its binding to NOS (48). 
Due to the flexibility of at least a portion of both elements none of the reductase domain 
structures yet published tell us about the exact position they have in the different 
functional conformations of NOS.  
  The autoregulatory region, or autoinhibitory loop, is an insert of 40-50 amino acids that 
lowers the affinity of constitutive NOSs for CaM with the result of making the enzyme 
sensitive to intracellular changes in Ca2+ concentration. The insert is in fact in a 
competition with CaM to bind the region between the two flavin domains. In addition, a 
role for the autoregulatory insert as a suppressor of electron flow to the heme domain 
apart from CaM involvement has been inferred: a truncated form of NOS lacking the 
insert, showed in fact a suboptimal production of NO even in CaM free condition, 
differently from the WT which has none. The C-terminal extension is present in all the 
three isoforms of NOS but has a different length, being 21, 33 and 42 residues long in the 
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inducible, neuronal and endothelial forms respectively. The deletion of the extension 
produces an enzyme with higher reductase efficiency in the absence of CaM; the deletion 
mutant activity has no difference with that of the WT when CaM is present. The role of 
the tail is consequently that of an interflavins electron-flow repressor in the CaM-free 
NOS. Though studies have shown a complexity in the role of this c-terminal tail (49, 50, 
51).  
   Further investigations analyzing a NOS reductase domain mutant lacking both the 
insert and C-terminal extension have been made; on the basis of this work a model 
relying on the concerted interaction of the two elements with CaM has been proposed 
(52). According to the model two different conformations are assumed by the reductase 
domain: a locked one where electron flow is allowed within the reductase domain, and an 
open one which lets electron flow to the heme domain. The switch between the different 
conformations is determined by the oxidation state of NADP(H): when oxidised NADP+ 
is released and no longer interacting with the C-terminal extension, which in turn is no 
longer capable to contact the autoregulatory insert. The loss of this contact determines the 
conformational change that arranges the reductase domain in order to donate electrons to 
the heme domain (open). 
   Activation of electron transfer by CaM binding is independent of the heme domain as 
CaM is has an activating effect on the isolated reductase domain. CaM binding doesn’t 
affect the reduction potentials of FAD and FMN, indicating that the triggering effect is 
based on a deep structural rearrangement that shortens the distance from FMN to heme, 
probably by inducing a degree of conformational mobility (53). 
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1.10 Heme domain 
 
The heme domain of NOS (Figure 1.14) consists of the approximately 400 N-terminal 
residues of the protein, though nNOS also has a preceding PDZ-binding domain. The 
heme domain, or oxygenase domain, as the name suggests, binds a b-type heme via a 
cysteine thiol linkage to the heme iron. All the NOS heme domains share a strong 
sequence homology, ~50%, and also share an overall tertiary structure.  
 
 
Figure 1.14 - A nNOS heme domain dimer showing the heme (red) and H4B (blue and 
green). The H4Bs lie within the dimer interface, which is approximately vertical in the 
above diagram (PDB file: 1OM4, unpublished paper). 
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   The quasi-globular structure of the heme domain is fairly rigid and has very few flexible 
portions. This has allowed for successful crystallography of the isolated heme domain. 
The largest portion of the domain, it would be hard to describe any subdomains as in 
NOSrd, is formed from the residues that compose the binding site of the substrate. These 
residues are highly conserved as the substrate must be specific and maintained in both the 
correct orientation to the heme iron and at the correct distance from it. Figure 1.15 shows 
the active site heme and residues. 
    The second important portion of the domain consists of the helical region below the 
heme concerned with the binding of H4B and dimerisation. This region contacts both with 
the H4B in its domain and the H4B of the partner domain in the dimer. This shared binding 
structure of H4B gives it a key role in the dimerisation of the enzyme.                          
   The heme is held by a proximal thiolate linkage, from Cys415 in rat nNOS. This leaves 
little space on the proximal side of the heme, but a relatively large binding pocket exists 
on the distal that forms the active site (54). On the rim of the heme are several 
hydrophobic residues that further stabilise binding, particularly Leu424, Leu559, Trp587, 
Met589, Val649, Phe704 and Tyr706 in rat nNOS. There are also stacking interactions 
from Phe584, on the distal heme, and Trp409, on the proximal. Trp409 also interacts with 
Cys415 and so may also have a role in modulating the electron density of the heme iron 
via the thiolate.   
   The active site binding pocket is formed by a large β-sheet whose residue side chains 




1.10.1 The active site 
 




Figure 1.15- Active site of nNOS. Below the heme plane is Trp409, which has stacking 
interactions with the heme, but also hydrogen bonds (dashed lines) to the cysteine thiol 
ligand. Above the heme is Phe584, with more stacking interactions. Gly586, the subject of 
mutation in this work is shown in the background in pink. To the left is Glu592, which via 
two hydrogen bonds to the substrate guanidinium positions the substrate over the heme 
iron. The substrate here in NOHA. H4B is shown in its position hydrogen bonded to the 
heme. (PDB 3HSN, Ref 56) 
 
This allows easy diffusion in and out of the site, but make for tightly controlled binding 
near the heme. The specificity of binding is important in NOS as the reaction of L-Arg to 
citrulline and NO happens asymmetrically. Both monooxygenation reactions occur on a 
single nitrogen of the guanidinium group. It is therefore important that this nitrogen be 
always held in close proximity to the heme iron, the site of reaction. The main interaction 
between the substrate and the active site in this positioning is a pair of hydrogen bonds 
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between Glu592 and the guanidinium group, Figure 1.15. This Glu is conserved in all 
mammalian NOSs. There is also a hydrogen bond between the non-heme orientated 
guanadinyl nitrogen and the peptide bond of Trp587, further strengthening this precise 
positioning.  
    The active site is limited in the size of compounds it can accept by Pro565, Val567 and 
Phe584 in rat nNOS.  The binding pocket can only accept L-amino acids, due to the 
position of the α-carbon of the substrate. The H bonds formed between the protein and 
the terminal α-carbon of the substrate involve the hydroxyl of Tyr588, the carboxylates 
of Asp597, Lys478 and a water molecule held by Arg603 with the carboxylate of the 
substrate; the α amino-group on the other hand interacts with the previously mentioned 
Glu592 and a heme propionate.  
  Work on inhibitors for NOS must, if they are competitive inhibitors, take into account 
all of these interactions. Many inhibitors simply do not mimic the interactions of the 
α−groups of the natural substrate. But they must in some ways be comparable to L-Arg if 




All mammalian NOSs have an absolute requirement for H4B, Figure 1.16. This is unusual 
as H4B is not a very common cofactor. As we shall see later though, its role in NOS as a 





Figure 1.16 - Structures of H4B, showing the ring numbering system used throughout this 
work, and H2B (57). 
 
The binding of H4B leads to dimerisation of the protein (58). On dimerisation there are 
various changes in conformation of the enzyme, in both the heme domain (59) and the 
reductase domain. The C-terminal portions of the heme domain are flexible and can 
change conformation depending on whether the protein is dimerised or not. When H4B is 
bound there are several residue interactions that stiffen these portions and aid in 
dimerisation. The binding site of H4B is on the dimer interface and both the protein 
partners interact with both H4Bs, strengthening the dimerisation Figure 1.17.  
H4B is bound at the dimer interface by hydrophobic interactions and stacking interactions 
by Trp678 and Phe690. The reduced tetrahydro-form of the pterin is deeply unstable (60) 
and readily undergoes a double oxidation to the inactive dihydro-form in solution. Since 
the role of H4B in NOS catalysis is as a one electron donor/acceptor the bound pterin must 
be stabilised to avoid a two electron oxidation to be of use. The bound H4B is far more 
stable than that in solution. The interactions of the protein with the pterin must therefore 
support the tetrahydro-form. The stacking of Trp678 is believed to stabilize the H4B 
radical by a π interaction. Mutagenesis of this residue allowed the formation of the pterin 
radical, but at a far reduced rate and stopped complete turnover of the enzyme. Phe690, 
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contributed from the other subunit, also stacks with H4B, stabilizing the dimer and also 
likely stabilizing the pterin. Vital to the mechanism is the ability of H4B to support a 
radical. Here again the residues that support binding also support the stability of this 
radical (61). 
 
Figure  1.17 - H4B, buried in the dimer interface, is stacked by a tryptophan (678) and a 
phenylalanine (690) from the facing monomer. The two subunits of the dimer are 
differentiated by being shown as blue and green. The heme propionate H-bonds with the 
3N of the pterin ring. (1OM4, Unpublished paper) 
  
  There are H-bonds from the nitrogen atoms of H4B to surrounding residues, further 
aiding binding and leading to a binding constant in the high nanomolar range. The most 
important interaction, however, is between the N3 of H4B and heme propionate. This is 
considered to be the path of electron transfer from H4B to the heme-bound oxygen and, as 
will become clear when the mechanism is discussed, is vital to the turnover of NOS (62).  
Aiding the activity of NOS is the preferential binding of H4B over the oxidized and 
inactive H2B form. This is because, on oxidation, the C6 on the second ring assumes a 
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trigonal planar geometry that clashes with the environment. Thus, should the bound pterin 
become fully oxidized it would be replaced by a reduced pterin. Also the steric hindrance 
experienced by H2B in the binding site would stabilise any H4B already bound. 
       All of these interactions must be considered in the design of H4B analogues. The 
design of analogues will be discussed further in the section of the mechanism directly 
related to H4B. 
 
1.12 Aromatic Amino Acid Hydroxylases 
 
H4B has an important role in another class of enzymes, the aromatic amino acid 
hydroxylases (63): phenylalanine hydroxylase (PheH), tyrosine hydroxylase (TyrH), and 
tryptophan hydroxylase (TrpH). These enzymes catalyse the reactions shown in Figure 
1.18 and are dependent on H4B for activity. 
 
 
Figure 1.18 - The reactions catalysed by the aromatic amino acid hydroxylases (63). 
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As discussed the most common, and therefore the most studied, mechanisms for 
hydroxylation in biology are the cytochrome P-450–dependent hydroxylases and the 
flavoprotein phenol hydroxylases. These are also easy to study with spectrophotemetry 
due to the bound cofactor heme or flavin. The aromatic amino acid hydroxylases are 
harder to study because they lack easy spectral changes to follow during the reaction, as 
they lack heme or flavin cofactors, relying on an iron-sulphur cluster.  
   What can be said with certainty is that the amino acid hydroxylases perform 
monooxygenation reactions, attaching one oxygen atom from dioxygen to the substrate 
and reducing, via two electrons, the other oxygen atom to water. In this overall reaction 
these hydroxylases are therefore very similar to each half step catalysed by NOS. 
  When the mechanism is observed though, the role of H4B is found to differ greatly 
between NOS and the aromatic amino acid hydroxylases. H4B in NOS donates electrons 
to the heme for oxygen activation, but is in turn reduced, finishing a catalytic cycle in the 
same state at which it started. In the amino acid hydroxylases H4B is consumed by the 
reaction, donating two electrons and ending the cycle as dihydroxypterin (64). This 
dihydroxypterin then must dissociate from the enzyme. In solution it will dehydrate to a 
quinonoid dihydropterin and must be converted back to the tetrahydro-form by 
dihydropteridine reductase. 
   Structures are available for all three enzymes with a pterin bound, allowing a close 
study of the binding of H4B. Figure 1.19, shows the major interactions of H4B in PheH. 
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Figure 1.19- Binding of H4B in PheH. Three hydrogen bonds exist between the nitrogens 
of the pterin and the protein backbone. These may alter on NADPH binding. Water 
mediated hydrogen bonds exist between the pterin and the iron (Orange). (PDB 1MMT, 
Ref 65) 
 
As can be seen most of the interactions are between the pyrimidine ring of the pterin, 
with the N1 and N8 of the pterin hydrogen bonding to a flexible loop of PheH. 
Interestingly only Ser251 interacts via the side chain, all the other interactions are via the 
peptide backbone (65). Ser251 hydrogen bonds to the dihydroxypropyl side chain of H4B. 
Since this residue is not conserved in TyrH or TrpH, this interaction does not seem to be 
key to the mechanism. However it must be taken into account in modelling of possible 
analogues that may wish to target specifically the PheH pterin binding site. 
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   Site directed mutagenesis has confirmed the importance of the electrostatic interaction 
between H4B and the carboxylate of Glu286. The dense series of interactions is also 
supported by a stacking interaction with Phe254. The complexity of all these interactions 
suggests the importance of H4B to the mechanism, but does it also confer a strong 
specificity for H4B over analogues? 
  Much work has been done on substituting the dihydroxypropyl side chain of the pterin 
(66), position 6, Figure 1.18. Replacing the side chain with a methyl group, 6-MePH4, 
gives a functional analogue in all three enzymes. Phenyl, ethyl, hydroxymethyl, and 
trihydroxypropyl side chains at the 6 position also yield functional analogues. A 
carboxylate side chain is not tolerated by the hydrophobic binding pocket and therefore is 
not functional.  2,4-Diamino-6,7-dimethyl-tetrahydropterin is reported to be a substrate 
for PheH suggesting that some expansion in the 7 position is tolerated, at least by PheH 
(67). All studies show that the pyrimidine ring is critical for function. 
  The mechanism of these enzymes, Figure 1.20, shows how different the role of H4B is 










































































Figure 1.20- Mechanism of aromatic amino acid hydroxylases, shown here for TyrH 
(68). 
 
In these enzymes there is direct chemical reaction between H4B and oxygen, something 
not observed in NOS. The roles of H4B cannot seemingly be directly compared then. It is 
tantalising that both these enzyme families use H4B for oxygen activation but the 
aromatic amino acid hydroxylases utilise a far less subtle mechanism.  
   For the design of analogues of H4B the roles and interactions of H4B with all these 




1.13 Cytochromes P450 
 
Any discussion of NOS mechanisms invariably begins with a comparison to cytochromes 
P450. This is because NOS mechanism is based on two monooxygenation steps. Each of 
the monooxygenation steps resembles the full reaction mechanism of a P450 
cyytochrome, as we shall see in this section. The P450 cytochromes are a large family of 
enzymes that usually perform mono-oxygenation reactions, Figure 1.21 (69). Dioxygen is 
bound at the heme, activated by reduction and an atom of oxygen is inserted into the 
substrate. These words could very well be used to describe the mechanism of NOS, but 
further similarities will also render comparison of NOS to the P450s edifying.  
 
RH +   O2 +   2H
+ +  2e- ROH + H2O
P450
 
Figure 1.21 - The generic mono-oxygenation reaction catalyzed by P450s. 
 
P450s have an active site based around a b-type heme that is thiol ligated from the iron to 
a cysteine residue. The strong electron donating nature of the thiolate is thought to 
activate molecular oxygen bound to the ferrous heme iron. This is also directly analogous 
to NOS. It would be tempting to say, given the similarities of heme and function that NOS 
and P450s are evolutionarily related, but no sequence analysis bares this out nor does 
structural comparison. It would seem to be a case of convergent evolution of mechanism. 
   P450s have been studied closely and much detail is known about their mechanism. 
Following the discovery of NOS it has been useful to compare their mechanisms. Let us 
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therefore consider the P450 mechanism. But first it must be noted the P450s generally 
lack a fused reductase domain to supply electrons and must therefore rely on an external 
source. Class 1 P450s use a complex two step delivery system involving ferredoxin 
reductase, which accepts electrons from NADH dehydrogenation, and uses FAD as a 
cofactor to accept the hydride. Ferredoxin reductase then reduces a second protein 
(containing an iron-sulphur cluster), ferredoxin. From ferredoxin the electrons are passed 
to the class 1 P450 heme. This complex system is most commonly found in bacteria and 
mitochondria. Class 2 P450s have a specific redox partner, Cytochrome P450 reductase. 
This reductase resembles the reductase domain of NOS closely as it derives electrons 
from NADPH, and uses FAD and FMN to traffic them on to the heme. While this may 
give some insight into the evolution of the NOSrd it is in the monooxygenation reaction of 
the P450s themselves that we may garner more knowledge of NOS mechanism (70). 
 
The mechanisms of P450s are so elegant in their details as to seem to transcend the 
phenomenological and enter the sublime. For the monooxygenation of hydrophobic 
substrates to occur molecular oxygen must be activated. Otherwise molecular oxygen in 
its triplet state would be unable to react with the substrate, typically in the singlet state. 
Transition metal ions are often used by enzymes for this purpose. In the case of P450s 
iron is used to activate oxygen due to its redox chemistry and ability to support highly 
reactive species. Once oxygen is bound to the heme iron two electrons, delivered 
sequentially, are required for reaction. The sequential delivery of these electrons gives rise 
to a number of intermediates which will prove useful in characterizing the intermediates 
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Figure 1.22 - A generalized P450 mechanism: 1- Substrate binding. 2- First electron 
transfer. 3- Oxygen binding. 4- Second electron transfer. 5- Formation of an oxy-ferryl 
species. 6 & 7- Rebound mechanism for oxygen insertion. 8- Product dissociation. 
Electron uncoupling leads to the production of superoxide, peroxide and water. (Adapted 
from Papale 2008) 
 
Following this mechanism step by step will help in later unraveling the NOS mechanism. 
1- Binding the substrate. The first step of the reaction is the binding of the substrate. 
This may seem an obvious first step, but in P450s the binding of the substrate often, 
though not always, involves the displacement of a loosely associated water molecule (71). 
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Here, as in NOS, the binding of the substrate changes the iron from a low to a high spin 
state. This change is easily seen spectroscopically. Unlike in NOS, the displacement of the 
water destabilizes the ferric form of the enzyme. Electrospectrometry shows a positive 
heme reduction shift on the binding of the substrate in P450 enzymes, by changes in the 
iron spin state. Binding the substrate therefore makes heme reduction far easier. 
 2- First electron transfer. As noted previously the electrons required for the reaction are 
supplied by a redox partner, derived ultimately from NADH or NADPH. Some P450 
enzymes undergo structural rearrangement on heme reduction that bring the substrate 
closer to the heme (72). This could be to ensure that electron delivery is tied to productive 
reaction and not the futile uncoupled reactions that generate reactive oxygen species such 
as superoxide or hydrogen peroxide.  
3- Oxygen binding. Molecular oxygen only has a strong affinity for the ferrous heme and 
binds rapidly to it. The iron-oxygen species could be described either as oxy-ferrous (FeII-
O2) or as the superoxy-ferric form (Fe
III-O2
-).  
4- Second electron transfer. The second electron donation from the redox partner to the 
heme leads to the formation of a peroxy-ferric species (FeIII-OO2-).  
5- Protonation. The mechanism then proceeds via a double protonation, the first of which 
produces a hydroperoxy-ferric intermediate (FeIII-OOH-). The hydroperoxy-ferric 
compound has also been suggested to be in some cases the reactive species, being reactive 
enough to perform the oxygenation especially when the second protonation is slow. 
However it is generally accepted that the hydroperoxyferric species is protonated and 
subsequently decays by loss of a water molecule to form a highly reactive carbocationic 
oxy-ferryl species (FeIV+=O), known as Compound I, with a heme based radical (73). The 
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Compound I has now been directly observed by EPR and Mossbauer spectroscopy in, and 
found to be catalytically competent in, the P450 CYP119 (74). Compound I has therefore 
been shown to be capable of performing a reaction we shall see occurring in NOS.   
6 and 7- Oxygen insertion. The oxy-ferryl compound is thought to remove a hydrogen 
atom from the substrate. This forms a substrate radical and a hydroxyferric heme species. 
Radical recombination would then rapidly occur to create a ferric heme and the final 
product.  This is termed the radical rebound mechanism (75). 
8- Product dissociation. The hydroxylated product is released from the ferric heme 
which binds a new molecule of water as sixth ligand. This mechanism is fairly simple and 
very elegant.   
   This mechanism took several years to elucidate but is now generally accepted. Under 
physiological conditions only the steps up to generation oxyferrous species can be 
observed by stopped flow reactions. The other intermediates required delicate work with 
Electron Paramagnetic Resonance (EPR), Electron-nuclear Double Resonance (ENDOR) 
and Raman spectroscopy to detect (76, 77). Work on stabilizing the intermediates 
involved mutagenesis and low temperature work, and gave direction on similar work on 
NOS. Compound I was observed by artificially generating it by the reaction of CYP119 
with m-chloroperbenzoic acid in stopped flow reactions. This allowed UV-VIS spectra to 
be taken, and also preparation for EPR and Mossbauer spectroscopy (74). 
   Applying this chemistry to both steps of the NOS reaction gives us a good starting 




1.14 NOS catalytic cycle 
 
Now we can apply the knowledge of the P450 mechanism to the NOS mechanism. The 
conversion of NO from L-Arginine takes place in two steps: the monooxygenation of L-
Arginine to L-NOHA and then the monooxygenation of L-NOHA to L-Citrulline and NO. 
Both of these steps can be considered monooxygenations but could be more properly 
described as first the hydroxylation of L-Arginine and then an oxidative scission of L-
NOHA to L-Citrulline. Each step requires molecular oxygen to be activated by reduction 
while bound to the heme. Here we shall consider what is known of the NOS mechanism 
and how it was elucidated. 
   Figure 1.23 shows a proposed mechanism for NO synthesis. Here the two steps are 
shown to be identical in terms of intermediates for simplicity, but they will be discussed 
further. Steps 1-5 are reciprocated in steps 6-11.                   
 57 
 
Figure 1.23 - Overall scheme of the NOS catalysed reaction here shown with a 
Compound I final species and both monooxygenation reactions following the same 
mechanism. This is not a universally accepted mechanism. 
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As seen in P450s the binding of substrate to NOS changes the heme high from a low or 
mixed spin state, to a high spin state, due to the displacement of a weakly associated water 
at the distal sixth position. This can be seen in the shift of the NOS Soret peak from 
400nm to 394nm. Unlike in P450s there is no shift in the reduction potential of the heme 
iron on substrate binding (78). 
     As we saw in the section in the reductase section the electron transferred from the 
FMN shuttling between the reductase domain and the heme domain reduced the ferric 
heme to the ferrous. Again, this step can be followed spectroscopically with a shift of the 
Soret peak from 394nm to 414nm. There is a change in the alpha/beta bands, a wide peak 
forms at 560nm replacing two very slight peaks at 530nm and 650nm. The band at 650nm 
disappears completely on reduction to the heme. The complete flattening of the peak at 
650nm is typically used to judge complete reduction of the heme to the ferrous state. 
Oxygen has a far greater affinity for the ferrous heme and it is after reduction that oxygen 
binds in the sixth axial position to form the oxy-ferrous species (79). This can be observed 
by UV/VIS as a shift in Soret peak to 425nm and sharpening of the 560nm band. This is 
only true for the substrate bound enzyme. In the absence of substrate there is no build up 
of the oxy-ferrous species, one only observes oxidation of the heme. This points to a 
stabilizing effect of substrate on the oxy-ferrous species  
   While discussing this first electron transfer it is useful to consider what happens in the 
uncoupled enzyme. The uncoupled transfer of electrons occurs when substrate or pterin, 
or both, is absent. In this condition electrons are delivered to the heme but without 
production of product. When substrate is absent the oxy-ferrous species will undergo 
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auto-oxidation and superoxide anions will be released (80). As has been seen the substrate 
stabilises the oxy-ferrous species, oxy-ferrous decay being seen at rates of 200s-1, 22s-1, 
and 4s-1 for the substrate free, Arginine-bound, and NOHA-bound nNOSoxy respectively. 
By control with CaM-binding the enzyme stops uncoupling by inhibiting the passage of 
electrons from the reductase domain to the heme domain. 
   After the oxy-ferrous species none of the other steps in the NOS mechanism can be 
viewed with UV/VIS under physiological conditions. This is due to the transient nature of 
these intermediates and they can only be detected with the techniques discussed for P450s 
and at low temperature.  
   Important insights into the second electron delivery have been gained from ENDOR 
characterization of intermediates at 77K by γ-irradiation of the oxy-ferrous species. The 
species formed was found to be a peroxy-ferric species, with a hydrogen bond to a water 
molecule (81).  
   However the identification of where the second electron comes from proved more 
tricky, as the second electron was delivered far more rapidly than the reductase domain 
was capable. The unusual and absolute requirement of NOSs for H4B made it a tempting 
source of this second electron. This hypothesis was given strength when a H4B radical 
(H4B
.) was detected after Rapid Freeze Quenching when arginine-bound Ferrous NOS 
was mixed with oxygen (82). Indeed the radical formed at the same rate as oxy-ferrous 
decay. This evidence was again strengthened by repeating the experiment with amino-
H4B, an analogue of H4B competent to dimerise the protein but unable to donate an 
electron to the mechanism. Here, no radical was detected and the oxy-ferrous decay was 
seen at a very slow rate. The experiment was again repeated with 5-methyl-H4B, an 
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analogue capable of donating electrons, the enzyme retains its capability to perform 
hydroxylation in a single turnover cycle and a pterin radical was detected. The rate of 
radical formation was three times faster then with H4B, and the rate of oxy-ferrous decay 
was also three times faster. At this point it would seem proven that H4B here acts as an 
electron donor, certainly in the reaction with arginine (83). 
   Proving the role of H4B in the second reaction step has been harder still. Detection of 
the pterin radical has been much harder. When it was detected it was found in much 
smaller amounts (3% compared to 75%, of heme content) (82). This could be due to the 
transient nature of the radical in the reaction with NOHA, being rapidly reduced. 
   In the first stage of the mechanism it is likely that the radical is reduced by an electron 
delivered from the reductase domain (83). This is a relatively slow affair and therefore the 
radical persists in the first step for longer. However after NOHA has been converted to 
citrulline the heme species that remains is a ferrous heme-NO complex. The ferrous 
heme-NO complex is so stable that it is considered a dead-end complex and NO will not 
be released. The H4B radical is a strong oxidizing agent and is assumed to oxidize this to a 
ferric heme-NO complex, thus regenerating a neutral pterin and the ferric heme. The ferric 
heme-NO complex will not long endure and NO is rapidly released. At this point the 
mechanism is complete and another cycle may begin. 
  So we can view H4B as a transient electron donor and acceptor, a totally unique role for 
the pterin and one much different from its role seen in the aromatic amino acid 
hydroxylases. 
  Prior to the discussion of the role of H4B we were up to the oxy-ferrous species in the 
mechanism. Now that we have seen H4B donating electrons to form the peroxyferric 
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species we can continue with some of the controversies of the mechanism.  
  It has been suggested by some that the final reactive species may be the peroxy-ferric 
(85). It is possible that it may be reactive directly with arginine or NOHA. But by 
comparison with P450s it is generally accepted that the peroxy-ferric species undergoes a 
double protonation and, via the loss of a water molecule, forms an oxy-ferryl species, 
Compound I (86). The evidence for this species, never directly detected, is that of the 
formation of a heme-substrate adduct, detected after two protonations and the loss of a 
water molecule in cryoreduction experiments (86). Here the substrate is coordinated to the 
ferric iron through the oxygen of the hydroxyl, having already undergone hydroxylation.  
The double protonation weakens the O-O bond, breaks it and produces the water 
molecule. This would, necessarily, lead to the formation of an oxy-ferryl species capable 
of reacting with the arginine nitrogen to produce the adduct. Further evidence comes from 
the formation of an adduct of NOHA and the heme. Once citrulline is then formed the NO 
remains bound to the ferrous heme until reduced by H4B as discussed in the section on the 










1.15 Aims of this project 
 
The physiological roles of NO make its production and regulation in the body vital. As 
this introduction has hopefully demonstrated the production of NO is sublime in its 
complexity and this work will help to explain some of the steps. The focus of this work is 
the mechanism of arginine hydroxylation and the role of the pterin in it. 
 
Can we characterize the stabilised intermediate of the NOS reaction formed by the 
G586S mutant? 
 
Previous study of a mutant with a serine introduced to the active site gave evidence of a 
stabilized intermediate in oxyferrous decay. The G568S mutant introduces a hydrogen 
bond to the substrate, stabilizing the binding of the substrate in the active site (See 
specific introduction to chapter 3). This intermediate, formed by the G586S mutant, 
forms after the donation of an electron from H4B. This points to the stabilised 
intermediate being the active oxidant in the mechanism. However, it has not been 
demonstrated that this stabilised intermediate in the G586S mutant nNOS is catalytically 
relevant or whether it is an artifact of mutation. By studying the mutant spectroscopically, 
by EPR, crystallographically with NOHA bound and the products of single turnover 





Can H4B act to rescue NOS from the ferrous heme-NO complex? 
 
The pterins in the NOS dimer are held with their conjugated π-systems only 13 Å apart. 
This has led to the suggestion that there may be electron transfer between the pterins, and 
therefore possibly between hemes in the NOS dimer. This would be of particular 
importance in releasing a heme from the dead-end ferrous heme-NO complex. However, 
no studies have ever been undertaken to study whether effective electron transfer does 
occur between the pterins. Here, we aim to correct that oversight. 
 
Can we find analogues of H4B that are both active and more stable to oxidation than 
H4B itself? 
 
The importance of NO, and therefore the importance of H4B to biological NO synthesis, 
means that H4B is a crucial target for drug design. Some people suffer from a deficiency 
of H4B. The unique qualities of H4B that make it so fascinating a molecule also make it 
unfit for oral administration. It is also unstable in the blood stream. It would be useful to 
find an analogue that could activate NOS and was more stable in solution than H4B. The 
creation of novel analogues of H4B would also be of scientific use in furthering our 

















All chemicals were purchased from Sigma, unless where otherwise stated. H4B and aH4B 
were purchased from Schircks lab (Switzerland). 
 
2.1 Preparation of cell lines 
 
All plasmids had previously been constructed. The full length nNOS gene (from Rattus 
norvegicus (Appendix 1)) in plasmid pcWori was kindly donated by Dr T. Shimizu 
(Tohoku University, Sendai, Japan). All nNOS heme domain constructs were created by 
Dr. Caroline S. Miles (Institute of Cellular and Molecular Biology, University of 
Edinburgh). The NOS G586S heme domain mutant characterised was generated by site-
directed mutagenesis. The E.coli strain BL21 was used for the expression of both wild 
type and G586S mutant constructs. During the creation of both wild type and G586S 
constructs, an N-terminal histidine tag was added to the C-terminus of the gene to allow 
purification by nickel affinity. To get correct protein folding in the bacteria the plasmid 
pGroESL was also transformed along with the nNOS plasmids (87). pGroESL codes for 
the mammalian chaperonin proteins. 
    Cell cultures for line-maintenance were prepared for the wild type full length, WT and 
G586S mutant nNOSoxy. Small amounts of cells were picked from the colonies on LB-
agar plates with a sterile wire loop and dispersed into 30 ml of autoclaved TB media with 
25 µg/ml carbenicillin, selective for pcWori, and 35 µg/ml chloramphenicol, selective for 
pGroESL, in sterelin tubes. This inoculated culture was then grown overnight at 37°C 
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while being shaken at 150 rpm in an orbital incubator. DMSO stocks for long term 
storage at -80°C were made by taking 930µl of this culture and adding 70µl DMSO 
before freezing. DMSO stocks were then used for future large growths. DMSO stocks 
were regularly remade to ensure cell line integrity. 
   For all growths the media used were prepared to the recipes in table 2.1.  
    
Growth Media and Agar 
LB Media For 1 litre: 10 g Bacto Tryptone 
                  5 gYeast Extract 
                  5 g NaCl 
TB Media For 1 litre: 20 g Bacto Tryptone 
                  10 gYeast Extract 
                  4 ml Glycerol 
                  2.6 g KH2PO4 
                  4.3 g K2HPO4 
LB Agar Plates 15 gL-1 agar dissolved in LB by autoclaving 
 
Antibiotics were added to the liquid agar once 
the agar was cool to the touch. 
 
Table 2.1- Guide to bacterial media preparation. All were made with MiliQ ultrapure 







Starter cultures were created by inoculating small volumes of TB media with bacteria 
from DMSO stocks. These were then incubated overnight at 37oC and 150 rpm in an 
orbital incubator. Aliquots of 2ml from the starter cultures were inoculate in each flask 
containing larger quantity of TB media: typically 20 x 450ml TB augmented with 25 
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µg/ml carbenicillin and 35 µg/ml chloramphenicol in 1 litre baffled flasks were used. The 
flasks were kept at 37oC and 150 rpm in an orbital incubator until the optical density of 
the culture was approximately 0.5 – 0.8 (~6 hours). IPTG (24 µg/ml) and ATP (113 
µg/ml) were then added to induce overexpression. The temperature of the incubator was 
lowered to 20oC for a period of 24 hours.  
  The cells were then harvested by centrifugation at 15000 rpm for 15 minutes at 4oC 
(Sorvall RC-5B centrifuge with a SLA 3000 head). Cell pellets were collected and stored 
at -20oC until required.  
 
2.3 Extraction and Purification 
 
For composition of the buffers used in purification see table 2.2. The collected cells 
pellets were defrosted and resuspended in Resuspension/Lysis buffer allowing 
approximately 4ml buffer per 1g of cell pellet. The thoroughly resuspended cells were 
lysed by ultrasonication with a Sanyo Soniprep 150. A typical preparation would use 5 
small glass beakers each containing 40ml of resuspended cells. Each beaker would 
receive 8 sonications of 30s each at 13 microns. Between sonication steps the beakers 
would remain on ice to prevent overheating of the sample and thoroughly mixed to 
ensure complete lysis of cells. After sonication the solution would be centrifuged at 
20000 rpm for 50 min using a Sorvall RC-B5 centrifuge with a SS34 head. This would 
pellet the cellular debris. The nNOS protein remains in the supernatant. Supernatant was 






Resuspension/Lysis Buffer 50 mM Tris-HCl (pH 7.5)  
0.5 mM EDTA 
10% glycerol 
0.3 M NaCl 
20 mM imidazole 
 
20 µM H4B* 
1 mM dithiothreitol 
25 mM phenylmethylsulfonyl fluoride (PMSF) 
0.1mM L-Arginine 
Protease inhibitor (1 tablet/50ml buffer) 
Elution Buffer 50 mM Tris-HCl (pH 7.5)  
0.5 mM EDTA 
10% glycerol 
150 mM imidazole 
0.3 M NaCl 
 
20 µM H4B* 
1 mM dithiothreitol 
0.1mM L-Arginine     
Gel Filtration Buffer 50 mM Tris-HCl (pH 7.5)  
0.1 M NaCl 
 
20 µM H4B* 
1 mM dithiothreitol 
 
Table 2.2- Protein preparation buffers. Chemicals shown in italics were added just prior 







2.3.1 Purification of nNOSoxy  
 
All protein purification steps were carried out in a cold-room at 4oC using gel filtration 
buffer with additions as stated below. The purification process for the WT and G586S 
nNOSoxy proteins were the same. 
The first step used a Ni2+ Sepharose (Sigma) column. This column material is composed 
of agarose beads linked to nickel ions by chelating groups. This purification step exploits 
the high affinity and extreme selectivity of the hexa-His tag cloned into the nNOSoxy 
constructs for Ni2+. This affinity allows for easy separation of tagged proteins from the 
lysate. Using a gravity feeding system the supernatant from the sonication step was 
loaded onto the nickel sepharose. The colour changes associated with loading, washing 
and elution can be seen in Figure 2.1.  
 
Figure 2.1- The purification of nNOSoxy with N-terminal hexa-His tag by affinity with a 
nickel sepharose. 
 
Load Elute Wash 
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The column was then washed with two column volumes of gel filtration buffer. The 
bound nNOSoxy leaves the column a dark red/brown colour. The protein is then eluted 
from the column using elution buffer. The high imidazole concentration displaces the 
hexa-His tag from the nickel. The eluting protein is then collected and concentrated using 
concentrators with a 30000MW cut off membrane (Vivascience). 
    Imidazole removal is performed by G-25 size exclusion chromatography. Excess 
imidazole must be removed as it has a high affinity for heme and will affect the protein’s 
performance in other experiments. Size exclusion uses column beads with pores of 
specific sizes to separate molecules based on size. Molecules small enough to enter the 
pores, such as imidazole, will take a longer path through the material and will be eluted 
last. Molecules too large to enter the pores will take a shorter path through the column 
and be eluted first.  Figure 2.2 shows the passage of nNOSoxy through a G25 column. 








Eluted protein was then concentrated and frozen for later use. The protein was 
concentrated by centrifugation at 2000 rpm in Vivaspin concentrators with a membrane 
size of 30000 MW. Protein concentration was calculated as described below and 
concentrating was ceased when the protein was at the desired concentration. Aliquots of 
~250-500µl of the concentrated, imidazole-free, protein were taken and flash frozen in 
liquid nitrogen. The samples of protein were then stored at -80oC until required. 
 
2.3.2 Purification of full length nNOS 
 
The previously constructed plasmid containing full length WT nNOS (T. Shimizu, 
Sendai) did not include a His tag. Purification of the full length protein relies on different 
affinity chromatography from the heme domain. 
   Sonication and centrifugation steps are the same as for the nNOSoxy proteins. The first 
step of purification for the full length enzyme is loading of the protein onto a CaM-
agarose column (Sigma). This column material has agarose beads cross-linked to 
calmodulin molecules. Here separation of the nNOS relies on its affinity for CaM. 
  Prior to loading the supernatant onto the column it is necessary to equilibrate the column 
with gel filtration buffer augmented with 1mM of CaCl2. This ensures the CaM is 
saturated with Ca2+ ions, necessary for binding to nNOS. The supernatant is also 
augmented with CaCl2  to a final concentration of 1mM.  
  After loading the column is washed with two column volumes of gel filtration buffer. 
This removes all proteins with no affinity for CaM.  
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  Elution is by gel elution buffer with 5mM of EGTA. EGTA is a chelating agent with a 
specific affinity for Ca2+ ions. By removal of the Ca2+ ions from CaM, the CaM loses the 
ability to bind nNOS and the protein is eluted.  
  The protein is then passed down a G25 size exclusion column equilibrated with gel 
filtration buffer. This removes excess EGTA, as it would interfere with turnover assays. 
  Protein was then concentrated and frozen as previously described for nNOSoxy. 
 
2.4 Protein characterisation 
 
Purity of the protein collected after chromatography was determined by Sodium Dodecyl 
Sulfate-PolyAcrylamide Gel Electrophoresis (SDS-PAGE). Reagents used for SDS-
PAGE are shown in table 2.3. SDS-PAGE was performed using NuPAGE Novex 4-12 % 
Bis-Tris pre-cast polyacrylamide gels. Size of proteins on the gel was judged by 
comparison with SeeBlue Plus 2 molecular weight markers. Protein samples for use in 
gel electrophoresis were prepared as shown in table 2.3. The samples were then boiled for 
3 minutes to denature the proteins and allow SDS binding. SDS binding is always one 
SDS molecule per two residues. This gives a constant charge ratio to the protein and so 
migration through the gel is dependent entirely on the protein mass. Use of pre-stained 









SDS PAGE buffers and stains 
Sample Preparation 25 µl NuPAGE® LDS 4x Sample preparation 
buffer pH 8.4 
25 µl diluted protein sample (>1 µM)  
50 µl dH2O 
Running Buffer NuPAGE® MES SDS 20x Running buffer 
pH 7.0 
Coomassie Stain 50 ml dH2O 
40 ml Methanol 
10 ml Acetic Acid 
1 ml Coomasie Brilliant Blue 
Destain 50 ml dH2O 
40 ml Methanol 
10 ml Acetic Acid 
 
Table 2.3- Sample preparation and buffers for SDS-PAGE. 
 
After preparation of the samples they were allowed to cool to room temperature for ease 
of loading. The pre-cast gel was placed in the running tank and running buffer added until 
the wells at the top of the gel were covered. To the first well pre-stained standard was 
added. Aliquots of protein sample were then added to subsequent wells. An electric field 
of 150V, 120mA and 60W was applied to the gel, and the gel left running until the dye 
reached the bottom. This allows for maximum separation and ease of size identification. 
After running the gel was stained in coomassie stain for 20 min and destained in destain 
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buffer for 1 hr.  Protein presence on the gel is indicated by the areas where coomassie dye 
remains on the gel, Figure 2.3 gives an example gel. 
 
 
Figure 2.3- Coomassie stained SDS-PAGE of the elution from the Nickel column. In the 
first lane there are size markers (SeeBlue® Plus2 Protein Standard, Invitrogen). In the 
second there is a sample of  flowthrough from the washing step. The final lane is the 
protein collected on elution of the column. nNOSoxy was the major component collected, 
band at approximately 80kDa. (Lanes edited together for ease of viewing) 
 
 
2.5 Concentration determination 
 
Calculating the concentration of nNOS was achieved by using the absorbance difference 
between the ferrous and ferrous-CO spectra of the enzyme. The extinction coefficient of 
this difference has been determined to be ε444-467 = 55, 000 M
-1cm-1 (80). Figure 2.4 
shows the spectra for each state. The UV/VIS spectra were recorded over the range 250 – 












reduce the protein. Once fully reduced, as judged by Soret peak position and absorbance 
at 650nm, CO gas was bubbled through the sample for several seconds. The spectrum for 
the ferrous-CO complex was then recorded. The ferrous spectrum was then subtracted 
from the ferrous-CO spectrum. Peak heights were then taken at 444nm and 467nm of this 
subtraction spectrum. Using the Beer-Lambert law allows calculation of the 
concentration of the protein. 
 
Figure 2.4- UV-Vis spectra of oxidised (black), reduced (red) and reduced CO-binding 
(blue) nNOSoxy. Ferric (substrate free) nNOS Soret peak has an absorbance maximum at 
400nm, ferrous nNOS at 412nm and ferrous-CO nNOS at 444nm. These are the same in 
WT and G586S nNOSoxy. 
 
2.6 Crystallography  
 
The general crystallographic approach used in this thesis will be discussed in the 
following pages with specific conditions for crystallography discussed in the relevant 
results chapters. The full range of conditions used in each trial can be found in appendix 
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2. Crystallography was attempted for the WT nNOSoxy with various H4B analogues and 
for G586S nNOSoxy with NOHA bound. When these substrates and cofactors were 
required they were used throughout the preparation and kept at constant excessive 
concentrations. 
2.6.1 Trypsin digest  
Trypsin agarose (Sigma) was used to cleave the PDZ domain from nNOSoxy proteins. 
This protease digestion is necessary for crystallography as the PDZ domain is mobile and 
impedes crystallography. Trypsin agarose, in a ratio of 1:100 (trypsin agarose: nNOSoxy) 
by weight, was added to the sample. The sample was left to digest at 4ºC for 24 hours 
under gentle stirring. To stop the digest the trypsin agarose was removed by filtration. 
The completion of the digest was judged by SDS-PAGE, Figure 2.5. 
 
Figure 2.5- Trypsin digest of nNOSoxy followed by SDS-PAGE. The first and last lane 
are markers (SeeBlue® Plus2 Protein Standard, Invitrogen) used to judge fragment size. 
From left to right of the sample lanes are times of digestion of 0, 1, 2, 3, 4, 5, 8, 10, 24 
hours. After 24 hours the oxygenase domain without PDZ domain predominates. It must 




2.6.2 Åkta separation of digestion products 
 
A Sephadex 200 size-exclusion column is used to separate the products of the trypsin 
digest on the basis of size. It separates the PDZ domain, undigested nNOSoxy and 
digested nNOSoxy domain. The elution of protein was followed by monitoring at 280nm. 
Heme was detected by measuring at 400nm. Fractions were collected and SDS-PAGE 
was run to identify proteins in it and the purity of the fractions. Those containing 
oxygenase domain without the PDZ were pooled and concentrated using Vivaspin 
concentrators with a 30000 MW cut off membrane. Concentrated protein was flash 
frozen and stored for later use.   
 
2.6.3 Protein crystallization 
 
 
Crystallization of the digested nNOSoxy domains (either WT or G586S) was  carried out 
by hanging drops, using 24 well Linbro® plates, respectively (Hampton Research). 
Hanging drops (4 µl volume) were prepared by adding 2 µl of 7-9 mg/ml protein 2µl of 
well solution. The particular well solution used for each protein sample will be discussed 





Figure 2.6- The set up of a hanging drop crystallography well. 
 
2.7 Pre-Steady-State Kinetics 
 
Pre-steady-state kinetic measurements were all carried out at 10 or 25oC using an 
Applied-Photophysics stopped-flow spectrophotometer (SX.17MV) connected with a 
diode-array detector. All stopped flow measurements were recorded under a nitrogen 
atmosphere in an anaerobic glove box (Belle Technology; [O2] < 5 ppm).  
 
2.7.1 Oxy-ferrous decay 
 
For studies of oxyferrous decay the formation of the oxyferrous complex was achieved 
by mixing ferrous enzyme with an oxygenated buffer. Oxyferrous decay was followed 
spectrophotometrically. All buffers used in the anaerobic box were bubbled with pure 
nitrogen before introduction to the box then allowed to equilibrate with the nitrogen 
atmosphere of the box for at least a day before use. Protein samples for use in stopped 
flow experiments was passed down a G25 column pre-equilibrated with degassed gel 
filtration buffer. This removed any oxygen from the sample and was used to introduce 
 
 




any substrate or cofactors required for specific experiments. Protein was generally diluted 
to approximately 10 µM. Ferrous nNOSoxy was generated by titration with sodium 
dithionite. Reduction of the protein was monitored by UV/VIS spectral changes in the 
heme absorbance. Titration with sodium dithionite was carefully performed so that no 
excess reductant existed in the protein sample. 
   For oxyferrous decay measurements the system was cooled to 10°C with ice. 
  Ferrous protein was then loaded into syringe A of the stopped flow machine. 
Oxygenated buffer (air saturated, ~200 µm O2) was loaded into syringe B. The two 
liquids were then rapidly mixed in the detector head and 400 spectra recorded over a time 
length of generally 1s. Experiments were repeated several times at several time lengths 
and data pooled. Data were analyzed using Pro-Kineticist 4.21 software (Applied 
Photophysics) software.  
 
2.7.2 Ferrous heme-NO decay 
 
The ferrous heme-NO complex of nNOS is considered a dead-end complex. It is tight 
binding and will only slowly decay without outside reactants. In reaction with oxygen it 
leaves a ferric heme and nitrate. These changes can be measured spectrophotometrically. 
All reactions were measured at 25°C. 
   WT nNOSoxy was treated as above for stopped flow reactions. After careful reduction 
with dithionite NO was titrated in. A 20ml sample of degassed gel filtration buffer was 
saturated with NO by bubbling with NO gas for 10min, this was used for NO titration.  
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  Differing amounts of NO were titrated into samples of reduced protein. An excess of 
NO was used on the first titration so as to gauge a maximal absorbance for the ferrous 
heme-NO complex. This was measured for the formation of the peak at 436nm. 
   The proportion of ferrous-NO heme to ferrous heme was calculated by comparing 
absorbances at 436nm and, once the stopped flow reaction was completed, 426 nm, the 
oxyferrous absorbance region. 
   Samples of nNOSoxy with varying amounts of NO titrated in were then reacted with 
oxygenated buffer. This then led to three reactions in the sample. The first was 
oxyferrous formation. This then decayed, in the second reaction. The third reaction was 
the reaction of the ferrous heme-NO complex with oxygen. As these occur on different 
time scales (the oxyferrous decay being three orders of magnitude faster than the ferrous-
NO decay) they could easily be modeled by Pro-Kineticist 4.21 software (Applied 
Photophysics) software.   
 
2.8 Turnover assay 
 
This assay for detection of the production of NO by NOS works on the shift in UV/VIS 
spectrum of hemoglobin when NO reacts to convert oxyhemoglobin to methemoglobin. 
  Oxyhemoglobin is prepared from bovine methemoglobin. A saturated hemoglobin 
solution is created by gentle stirring of solid hemoglobin over several hours in gel 
filtration buffer. This is then filtered to remove any debris. To this solution 20mM 
sodium dithionite is added. The reduced hemoglobin is then passed down a G25 size 
exclusion column. This removes excess dithionite and allows the reaction of the ferrous 
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hemoglobin with oxygen. As the hemoglobin reacts to form oxyhemoglobin there is a 
visible colour change, the protein should become vibrant red. The oxyhemoglobin is 
collected and flash frozen for later use.  
   A reaction mixture of 1ml is created containing a final concentration of: 50mM 
Tris/HCl buffer, pH7.5, 10µM oxyhemoglobin, 0.1mM NADPH, 10 units/ml superoxide 
dismutase, 100 units/ml catalase, 10µg/ml CaM, 250nM nNOS (prepared in the absence 
of any pterin cofactor), and pterin at desired concentration. Pterins are prepared for use 
from solid, under a nitrogen atmosphere, in a buffer containing 1mM dithiothreitol, and 
stored on ice. The reaction mixture is incubated at 25°C for ~1 min to allow for 
dimerisation of the enzyme and binding of the analogue.  
  The cuvette containing the reaction mixture is inserted into the spectrophotometer, set to 
401nm, and zeroed. Measurement is started. Due to uncoupled reactions there may be a 
slight decrease in absorbance measured. The turnover reaction is then started by the 
addition of L-Arg to a concentration of 1mM. If the pterin is an active cofactor then NO 
will be produced. Figure 2.6 shows the sort of trace produced by these experiments. 
   NO converts oxyhemoglobin to methemoglobin. The rate of NO production is then 




Figure 2.7- Results for a turnover assay for an analogue of H4B.  Absorbance is 
measured at 401nm. Rate of NO production is calculated from the linear portion of the 
graph, demarked in red. 
 
2.9 Peroxide shunt reaction 
 
It has been noted before that nNOSoxy can produce NO from NOHA if also in the 
presence of hydrogen peroxide (88), this is referred to as the shunt reaction, and is well 
demonstrated in cytochromes p450. However nNOSoxy will not perform the first 
monooxygenation step of L-Arg to NOHA. Also the product of the peroxide driven shunt 
reaction of NOHA leads to the formation of NO with L-citrulline and cyanoornithine in 
equal quantities. Under normal turnover conditions only L-citrulline is produced. The 





Figure 2.8 - The Griess reaction used in the detection of nitrite. The λmax of the azo 
product is 540nm. 
 
  Direct detection of NO is difficult so nitrite (a rapidly produced breakdown product of 
NO with O2) production by wild-type and G586S nNOSoxy was determined using the 
Greiss reagents (89) sulfanilamide and N-(1-naphthyl)ethylenediamine following the 
peroxide shunt assay. The product of the Griess reaction, a pink azo-dye, was measured 
by taking the absorbance at 540nm, Figure 2.8 shows the Griess reaction. The assay mix 
consisted of a 100µl reaction mixture prepared in 50mM Tris buffer pH7.5 with either 
250nM nNOSoxy WT or nNOSoxy G586S, 0.1-1000 µM H4B, 1mM NOHA, 0.5mM 
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DTT, 10units/ml SOD and 0.5mg/ml BSA. The reaction was initiated by the addition of 
hydrogen peroxide added to a final concentration of 30mM. The reaction was incubated 
at 25˚C for 10 mins and quenched with the addition of 1500 units of catalase. 
  At the beginning of each set of experiments a concentration curve for standard nitrite 
solutions reacted with the Griess reagents was derived to allow accurate concentration 
measurement.   
 
2.10 Single turnover  
 
To test the catalytic activity of the G586S mutant without creating the full length mutant 
single turnover reactions using the heme domain were used (90). These single turnover 
reactions mimic normal turnover exactly except they use dithionite as the external source 
of electrons instead of the reductase domain and they are only capable of performing a 
single monooxygenation step (either L-Arg to NOHA, or NOHA to citrulline). 
   nNOSoxy (WT or G586S) was introduced to a nitrogen atmosphere within an 
anaerobic box. Oxygen was removed from the sample by passing down a G25 size 
exclusion column pre-equilibrated with degassed 50mM Hepes buffer, 0.1M NaCl, 
1µM H4B, pH 7.5. The protein was reduced by careful titration with sodium dithionite, 
complete reduction being judged by a destruction of absorbance at 650nm.  
  Samples of 1ml protein, of approximately 50 µM, had either L-Arg or NOHA added 
to a concentration of 150µM. Samples were then removed from the anaerobic box and 
exposed to atmospheric oxygen for several minutes. The reaction solution was 
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separated from the protein by centrifuging the reaction sample in Millipore filters with 
10000 MW cutoffs. 
  The reaction solution was then either used directly for derivatisation of amino acid 
products or frozen for later use (91). o-phthaldialdehyde (OPA) reagent (1mM OPA, 10 
v/v methanol, 1v/v β-mercaptoethanol) was prepared and stored at 4˚C for up to 48hrs. 
80µl of sample was mixed with 20µl of OPA reagent for 1 minute before use in HPLC. 
OPA derivitised amino acids are detectable by fluoroscopy. After derivatisation a 20µl 
sample was injected onto a Phenomenex hypersil 250 x 10.00 mm column, 5 micron 
particle size. The column was eluted under the following conditions. Buffer A= 5% 
acetonitrile, 15mM sodium borate with 0.1 v/v trifluoracetic acid, pH 9. Buffer B= 50% 
acetonitrile, 8mM sodium borate, 0.1 v/v trifluoroacetic acid, pH9. The solvent 
gradients were linear and as follows; Flow rate 1.5 ml/min. 0-10 min= 0-12% buffer B. 
15-26 min= 12-85% buffer B. 31-36 min= 85-0% buffer B. 36-50 min at 2 ml/min, 
100% buffer A. OPA-derivatised citrulline, NOHA and arginine eluted at 30.8, 31.2, 
and 32.2 min respectively as easily resolved peaks. Fluorescence was detected by 
excitation at 360nm and emission at 455nm using a Gilson 122 fluorometer. Each 




WT and G586S nNOSoxy protein was prepared as described above. It was then passed 
down a G25 size exclusion column pre-equilibrated with a standard phosphate buffer 
(KPi 0.1M, pH 7.4, no Glycerol, no salt) to exchange the buffer. The resulting protein 
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in phosphate buffer was concentrated to 150 µM. No substrate, L-arg or NOHA was 
added to the protein at a concentration of 300 µM depending on the conditions to be 
tested. The protein was then reduced carefully with sodium dithionite so as to leave no 
excess. After reduction of the protein sample NO gas was bubbled through the sample 
for several seconds and the sample sealed. The protein was then flash frozen in liquid 
nitrogen and sent to Jerome Santolini and Pierre Dorlet (Institut de Biologie et de 
Technologies de Saclay, Saclay, France) who recorded the spectra shown in Figure 3.5. 
The 9.4 GHz (X-band) EPR spectra were recorded on a Bruker ELEXSYS 500 
spectrometer equipped with a standard TE cavity (Bruker) and an Oxford Instrument 
continuous flow liquid helium cryostat and a temperature control system. Simulations 



























3.1 Introduction  
(Previous work on G586S mutant by Davide Papale and Chiara Bruckman) 
 
As stated in the introduction there is still much discussion on the details of the 
mechanism of NOS. Argument hinges on the active species of the heme capable of 
performing the monooxygenation. An oxyferryl heme radical cation (Compound I), as is 
found in the mechanism of cytochromes P450, seems a sound candidate and DFT 
calculations support its role in NOS (92). No direct detection of this intermediate has 
been made in NOS however.  
  It must also be remembered that NOS carry out two monooxygenations; the first on L-
Arg and the second on NOHA. Most research assumes that the two steps are different in 
mechanism, favouring a peroxy ferrous active species for the second monooxygenation 
(93).  Certain portions of both steps are known. For instance, a pterin radical is formed 
for both substrates. After the binding of an oxygen molecule to the ferrous heme then 
both steps proceed via the donation of an electron from H4B. Both steps then continue via 
a peroxo ferric complex. It is after this point in the mechanism, steps 2 and 7 in Figure 
3.9, that remains unclear and the role of H4B must be defined. 
    The residues of the distal active site of nNOS act to stabilise and activate the oxygen 
species formed on the heme iron via positioning of the substrate. They aid in promoting 
oxygen binding and cleavage of the O-O bond. They do this by the precise positioning of 
the substrate guanidinium group (21). However, there are no hydrogen bonds directed at 
the space where substrate and oxygen react. Cytrochromes P450 do have hydrogen bonds 
in the active site which interact with heme-bound oxygen, usually stabilizing water 
 89 
molecules in the active site to act as a proton transfer pathway (94). Protons are necessary 
for oxygen activation, see Figure 3.9 steps 2 and 7. Introducing a hydrogen bond to the 
active site of NOS may alter the rate of reaction or stabilise an intermediate, as has been 
seen previously (95). Therefore a mutation was introduced converting an active site 
glycine to serine (G586S). This mutation was created in the nNOSoxy construct and 
characterised spectroscopically and crystallographically.  
  The G586S mutation was found, by stopped flow reactions following oxy-ferrous decay, 
to stabilise an intermediate, Figure 3.1. 
Rates of decay for the novel intermediate were derived and can be seen in Figure 3.1. The 
intermediate does not resemble a simple overlaying of other states and decays with a 
single rate.  
 Intriguingly the intermediate was not observed if oxyferrous decay was performed with 
the redox inactive H4B analogue 4-amino-H4B (aH4B). This allows us to position the 
intermediate within the putative mechanism for NOS. The intermediate would seem to be 
the product of the donation of an electron from H4B to the oxyferrous heme. This would 
place the observed intermediate in the portion of the mechanism for which there is least 
information, that of the active oxygenating species. If the stabilised intermediate 
observed in G596S could be shown to be mechanistically active then it could prove a 
valuable tool in unraveling the mechanism of NOS. Further work was undertaken to 





A                                      
B
G586S + L-Arg G586S + NOHA
nm nm
 
Figure 3.1- The G586S mutant was probed by stopped flow reaction of the reduced protein with oxygen. 
This forms the oxyferrous complex, and the decay of that species can be followed spectroscopically. A) 
Shows the spectra observed during oxyferrous decay of WT and G586S nNOSoxy, with L-Arg bound. Note 
the shift in the position of the oxyferrous peak in the mutant. B) During the decay of the oxy-ferrous 
species, green, in the G586S mutant a species previously unobserved, pink, in the WT is seen to form Dark 
blue is the ferrous heme, light blue the ferric heme. The intermediate was detected by fitting the observed 
data of oxyferrous decay to a triphasic mechanism. An extra intermediate is observed with either L-Arg or 
NOHA bound to G586S, with the same absorbance maximum. Spectra gathered at 10°C. 
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    Affinity titrations showed that the introduced serine residue, likely due to the 
introduced hydroxyl on the side chain forming a hydrogen bond, stabilised the binding of 
arginine. Arginine affinity was increased by a factor of 10 in the G586S mutant, from 
1.0µM in the WT enzyme to 0.1 µM. NOHA binding affinity was also increased from 0.9 
µM in the WT to 0.5 µM. This shows a preference for arginine binding over NOHA in 
the mutant that is not present in the WT.  
   In WT nNOS the Kd of NO binding to the ferric heme in the absence of substrate was 
calculated as 2.5µM, decreasing to 6.9 µM and 20.3 µM in the presence of L-Arg and 
NOHA respectively. The introduced serine residue was not seen to significantly alter the 
binding of NO to the ferric heme of the mutant in the absence or presence of substrate, 
Kds of 1.8, 3.2 and 2.2 µM were measured for G586S nNOSoxy substrate free, with L-
Arg or NOHA respectively. The with-substrate binding affinities of diatomic ligands in 
the mutant are significantly higher than the WT enzyme however. 
   The binding of CO was used to probe the ferrous heme. Here either substrate was found 
to increase the binding affinity by ~10x in the mutant compared to WT. In summary the 
G586S mutation has little effect on the binding of diatomic ligands in the absence of 
substrate but increases the affinity with substrate. This suggests a substrate mediated 
interaction between diatomics bound to the heme and the introduced serine. It was 
suggested the stabilising of binding may be due to a repositioning of the substrate through 
interaction with the serine. A new interaction between heme binding diatomics and the 
guanidinium group of the substrate may have been introduced. 
  This was subsequently confirmed by x-ray crystallography which yielded a structure of 
2.6 Ǻ resolution (PDB 3FC5, unpublished paper). This structure, from a crystal grown 
 92 
with protein prepared by the present author, showed no gross structural change in the 
enzyme. As Figure 3.2 shows the hydroxyl of the serine residue is indeed within bonding 
distance of the guanidinium group of arginine, with a distance of 2.9 Ǻ. The extra 
hydrogen bond would account for the 10 fold increase in binding affinity for L-Arg. 
Modeling suggests that NOHA would also be able to support this hydrogen bonding. 
However, the additional hydroxyl that NOHA has could clash with the serine residue. 
This would account for the difference between the binding affinities of arginine and 
NOHA seen in the mutant. A crystal structure of the mutant with NOHA binding would 







Figure 3.2- The active site of the G586S mutant with L-Arg bound. S586 is seen to 
contribute an extra hydrogen bond to the substrate, as predicted by binding affinities. It 






A major part of this project has been concerned with elucidating whether the mutant is 
catalytically competent to produce NO. As shall be seen this question has been solved 
and the role and identity of the stabilised intermediate can be theorised. 
  To confirm and add to the work already done on this mutant several experiments were 
required. A crystal structure of the mutant with NOHA bound was sought to confirm 
substrate orientation. EPR experiments were used to probe the active site interactions 
with a diatomic ligand bound at the heme. Finally a method of checking the catalytic 





3.2 Crystallographic studies of G586S   
(With Laura Campbell, University of Edinburgh) 
To aid in further understanding of the differences between the two monooxygenation 
steps of NOS, and specifically in the G586S mutant, a crystal structure of the G586S 
mutant with NOHA bound was sought to complement that already gained with L-Arg. 
Any differences in binding orientation detected in the crystal structure would aid in 
interpreting the data gained in binding affinities and other reactions. 
    Following purification of the G586S nNOSoxy and digest with trypsin to remove the 
mobile PDZ domain, as described in Materials and Methods, suitable protein for 
crystallography was collected. Using the conditions previously found (Unpublished data, 
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D. Papale and C. Bruckman) to suit crystallisation of the mutant with arginine several 
hanging drop trays were prepared around these conditions. 0.1M MES (2-(N-
morpholino)ethanesulfonic acid) of pH ranging from 5.8-6.5 was used. Also varied in our 
trials was the concentration of polyethylene glycol, 3350Da, 20-25%. All other chemicals 
in each well were kept constant. These were 0.2M ammonium acetate, 2% isopropanol, 
50mM Sodium Dodecyl Sulfate (SDS), and 50mM glutathione. 2µL of well solution was 
mixed with 2µL of protein (6-8 mg/ml) and placed upon a coverslip. 
   NOHA was added to the protein and the well solutions at a concentration of 150µM. 
This vast excess of substrate was used to ensure full occupancy of the active site and to 
facilitate dimerisation.  
  A crystal was found after 5 days of crystallisation, see Figure 3.3. 
 
Figure 3.3- The rod shaped crystal gained for G586S nNOSoxy with NOHA. 
 95 
 
The variable conditions used to grow this crystal were as follows. The protein 
concentration was 6 mg/ml, pH 6.5, 25% PEG. Unfortunately this crystal shattered as it 
was removed and frozen. Possible conditions for crystallisation have therefore been 
found. There was not sufficient time in this project to gain the crystal structure as to 
successfully grow a useable crystal would likely haven taken months of repeated attempts 
in varying conditions, as it did with the G586S with L-Arg crystal. 
 
3.3 EPR studies of G586S 
 
Without a crystal structure to supply information on the binding of NOHA in the active 
site an alternative experiment was sought to probe the active site interactions of the 
G586S mutant. EPR (Electron Paramagnetic Resonance) studies allow the probing of 
interactions of the ferrous heme-NO complex. The stability of this complex makes it ideal 
for these studies. The ferrous heme-NO complex is a good analogue of the oxyferrous 
complex and may point to important interactions between the substrate, active site 
residues and the diatomic ligands. Such studies allowed the probing of hydrogen bond 
networks in the active site by comparison of the WT enzyme with the G586S mutant, 
with and without substrates. 
   WT and G586S nNOSoxy protein was prepared to concentrations of 150 µM in a 
standard phosphate buffer (KPi 0.1M, pH 7.4, no Glycerol, no salt). The protein was then 
reduced carefully with sodium dithionite so as to leave no excess. After reduction of the 
protein sample NO gas was bubbled through the sample for several seconds and the 
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sample sealed. The protein was then flash frozen in liquid nitrogen and sent to Jerome 
Santolini and Pierre Dorlet (Institut de Biologie et de Technologies de Saclay, Saclay, 
France) who recorded the spectra shown in Figure 3.4. 9.4 GHz (X-band) EPR spectra 
were recorded on a Bruker ELEXSYS 500 spectrometer equipped with a standard TE 
cavity (Bruker) and an Oxford Instrument continuous flow liquid helium cryostat and a 
temperature control system. Simulations were performed by using the Easyspin software 
package. When required the substrates were added to the samples in excess. These results 
confirmed several predictions regarding the binding of substrates at the mutant active 
site. Figure 3.4 shows the main results of these studies. 
 
Figure 3.4- EPR results indicating the interactions of the ferrous heme-NO complex in 
WT and G586S nNOSoxy with various active site occupancies. Protein was 150 µM and 




These results closely resemble those previously gained for nNOS (86). As can be seen in 
Figure 3.4, and from the g –values in table 3.1, the binding of arginine does not greatly 
affect the profile of the ferrous-NO spectrum in either WT or mutant.  
 
Protein Sample g-values 
WT (No substrate) 2.086, 2.005, 1.970 
WT (Arginine) 2.085, 2.004, 1.970 
WT (NOHA) 2.077, 2.005, 1.986 
G586S (All conditions) 2.084, 2.005, 1.973 
 
Table 3.1 – Table of g-values derived from EPR experiments on WT and G586S 
nNOSoxy (Ferrous-CO complex). Note only WT nNOSoxy with NOHA bound displays 
a markedly different spectrum. G586S nNOSoxy gave the same spectrum with either 
substrate, or none. 
 
This suggests a very limited interaction between arginine and the heme-bound NO in 
both proteins, despite both proteins displaying a far greater affinity for NO when L-Arg is 
bound compared to substrate free.  The binding of NOHA in the WT protein causes a 
large shift, 2.077 compared to 2.085 on L-Arg binding. This reflects an introduced H-
bond network on NOHA binding that alters the ferrous-NO geometry (96). Interestingly 
this does not occur in the G586S mutant with NOHA, whose spectrum most resembles 
that of the G586S mutant with arginine. This can be explained by NOHA having a quite 
different binding orientation in the mutant than in the WT. As has been suggested in the 
introduction to this chapter, the introduced serine residue could clash with the NOHA 
hydroxyl group. It may be the interaction between this NOHA hydroxyl and the ferrous 
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heme-NO complex that leads to the different EPR spectrum in the WT. If there is a clash 
in the mutant, the NOHA would bind (since we know it does bind) in a different 
orientation. In this other orientation the NOHA hydroxyl may be orientated away from 
the heme. This would explain the seeming lack of interaction between NOHA and the 
ferrous heme-NO complex. It would be useful to have a crystal structure of the G586S 
mutant with NOHA bound to confirm this interpretation.   
 
Catalytic competency of G586S 
 
3.4 nNOSoxy peroxide shunt reactions 
 
As mutagenesis of the full length enzyme to G586S proved difficult other experiments 
attempting to probe the catalytic competency of the mutant were attempted using just the 
oxygenase domain. The hydrogen peroxide driven ‘Shunt’ reaction is well known for 
P450 oxygenases. Hydrogen peroxide is thought to react with the ferric heme to form a 
peroxo-ferric species directly, bypassing several steps of the normal mechanism. The 
peroxo-ferric species then undergoes a heterolytic O-O bond cleavage to produce a 
Compound I intermediate that performs substrate oxidation (97).  
   Hydrogen peroxide has also been shown to be able to convert NOHA to citrulline in the 
presence of NOS (85) and so was used here to test catalytic competency of the mutant 
here.  
Wild type and G586S nNOSoxy were tested for their ability to produce nitric oxide from 
NOHA using the peroxide shunt assay. Reaction of either enzyme with hydrogen 
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peroxide, but no substrate, gave no production of nitrite as judged by the Greiss reaction. 
Both enzymes proved capable of producing NO from NOHA by the shunt reaction. Both 
enzymes reached their maximum catalytic rate in the presence of approximately 
stoichiometric H4B. Under these conditions wild-type and G586S nNOSoxy produced 
0.142 ±0.011 and 0.154 ±0.005 mol of nitrite per mol enzyme respectively in 10 min 
assays as measured using the Greiss reaction for the detection of the breakdown products 
of NO (data not shown). In these assays, nitrite results from the production of NO, 
indicating that the mutant is as catalytically competent as the wild-type enzyme in 
performing nitric oxide synthesis under these conditions. 
  The qualification ‘under these conditions’ is important in reference to the ‘shunt’ 
reaction of NOS. Previous work has shown that the reaction is only capable of the second 
of the monooxygenation steps, which most researchers take as evidence that the two steps 
do not use the same mechanism. A second concern is the significant formation of cyano-
ornithine, Figure 3.5, in this reaction (98). Cyano-ornithine has never been detected in 
normal turnover conditions and its presence as a significant product may raise doubts 
over whether the shunt reaction provides reliable data on catalytic competency. While 
NO is certainly being produced it is possible that the shunt reaction is not following the 
normal mechanistic pathway for NOS. 
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Figure 3.5- Cyanoornithine, a major byproduct of the peroxide shunt reaction of NOHA 
in NOS. 
    As well as these limitations it was also found that hydrogen peroxide and NOHA in the 
presence of hemoglobin is capable of producing NO, as judged by the Greiss reaction 
(data not shown). This suggests that the reaction is non-specific to the highly regulated 
environment of the nNOS active site, but capable of occurring at a non-specific heme. 
This ability of a non-NOS hemoprotein to support the peroxide shunt driven creation of 
NO from NOHA may offer further mechanistic insights, but requires more study than it 
has been possible to give in this work. The experiments of this reaction were limited and 
qualitative, but may be of interest. 
 
3.5 Single turnover reactions 
 
Single turnover reactions mimic exactly the conditions of normal turnover of the enzyme, 
but are capable of only single monooxygenations. That is, they can convert arginine to 
NOHA and NOHA to citrulline and NO. These reactions rely on the external delivery of 
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electrons, due to the absence of a reductase domain in this case as nNOSoxy was used for 
both WT and G586S experiments. Here sodium dithionite was used to reduce the heme 
by careful titration to ensure no excess dithionite provided excess electrons to the 
reaction. Once reduced the enzyme is then in the same state as it would be in normal 
turnover after the delivery of the first electron from the reductase domain (step 1 of the 
mechanism as shown in Figure 3.9). The protein is then exposed to oxygen, which binds 
to the heme. The reaction then continues using an electron donated from the pterin. The 
substrate should then be converted to the product of whichever monooxygenation step is 
being tested. L-Arg would be unable to undergo the second monooxygenation though as 
further electrons, normally reductase domain derived, would be unavailable. These single 
turnover reactions should therefore allow the complete probing of a catalytic cycle of the 
mutant enzyme and reveal competency. 
   To follow these reactions, as no NO would be produced by the first monooxygenation, 
product analysis of the amino acid substrates and products (l-Arg, NOHA and citrulline) 
by HPLC was used. To allow detection of the amino acids they were derivitised with 
OPA, as stated in the materials and methods. The following three Figures (figs. 3.6, 3.7, 
and 3.8) are representative of the results gained by HPLC analysis of the products of 




Figure 3.6- Fluorescence traces of the OPA-derivatives of L-Arg, NOHA and citrulline 
as they were eluted from the HPLC column as controls. Reaction mixtures were prepared 
(50 µM nNOSoxy, 150 µM amino acid, 1 µM H4B), but not reduced by dithionite, and 
protein removed by centrifugal concentrator. 80 of the solution was mixed with 20 OPA 
solution, allowed to react for 1 minute. 20 of the derivitisation mix was injected into 
hypersil reverse phase column, running conditions in materials and methods. Product 
elution was detected by fluorescence at 455nm (excitation wavelength 360nm). Elution 





Figure 3.7- Single turnover results for WT and G586S with NOHA. A) The first trace 
shows the control elution trace for NOHA derivatised with OPA. B) The second trace 
shows the elution trace for the WT single turnover reaction minus the standard. The 
peaks at 30.1 and 32.1 min show amino acid products of the single turnover reactions. 
Citrulline appears to have been produced from NOHA by the WT enzyme. C) The third 
trace shows the elution trace for the G586S single turnover reaction minus the standard. 
The peaks at 30.1 and 32.1 min show amino acid products of the single turnover 
reactions. Citrulline appears to have been produced from NOHA by the G586S mutant. 
As separation of amino acids was not complete, to make the results clear the standard 
elution trace of NOHA was subtracted from the reaction product traces to easily view the 




Figure 3.8- Single turnover results for WT and G586S with L-Arg. A)The first trace 
shows the standard elution trace for L-Arg derivatised with OPA. B) The second trace 
shows the elution trace for the WT single turnover reaction minus the standard. The peak 
at 31.1 min is characteristic of NOHA. NOHA appears to have been produced by the WT 
enzyme by these single turnover reactions. C) The third trace shows the elution trace for 
the G586S single turnover reaction minus the standard. The lack of any major peaks 
suggest the G586S was unable to react with arginine under single turnover conditions. 
See text for explanation. As separation of amino acids was not complete, to make the 
results clear the standard elution trace of NOHA was subtracted from the reaction product 







As Figure 3.6 shows the separation of arginine, NOHA and citrulline was not completely 
resolved, with elution times of 32.2, 31.0, and 30.7 minutes respectively, but they were 
sufficiently separated to allow for analysis.  
  Figure 3.7 shows the traces recorded for the HPLC analysis of the reaction mixture, 
without enzyme, and the difference traces of the single turnover reactions of the G586S 
mutant and WT enzymes with NOHA, as followed by OPA derivitisation of amino acids 
in the reaction mix after the reaction. These reactions mimic the second 
monooxygenation step and were performed to confirm the previously gained results from 
the peroxide shunt mechanism. The difference traces were calculated by simply 
subtracting the trace of the reaction mixture from the trace recorded for the single 
turnover. This was done to allow ease of comparison due to the lack of complete 
separation. The difference trace for the single turnover reaction of WT enzyme with 
NOHA shows a negative peak at ~31min elution time, corresponding to NOHA 
consumption. This results from the consumption of NOHA in the single turnover 
reaction. The same is seen for the G586S mutant. A peak appears at 30.1 min, 
corresponding to citrulline. This suggests that NOHA has been converted to citrulline 
under these conditions by both the WT and mutant enzyme. It should be noted that there 
is a significant, though minor, extra product in the NOHA single turnover steps. It is 
unclear what this product may be, but it appears in both the WT and mutant reactions and 
should perhaps be seen as an artifact of the single turnover technique, much as cyano-
ornithine is seen in the peroxide shunt reaction (though this minor product is at a much 
lower proportion than that of cyano-ornithine in those experiments) (98). 
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  Figure 3.8 shows the traces for the HPLC analysis of the reaction mixture, without 
enzyme, and the difference traces of the single turnover reactions of the G586S mutant 
and WT enzymes with L-Arg. The difference trace for the WT enzyme shows a negative 
peak at ~32 min elution time corresponding to L-Arg, showing its consumption in the 
single turnover reactions. There is also a peak at ~31 min, suggesting the production of 
NOHA by the WT enzyme from NOS, as would be expected. However the difference 
trace for the G586S mutant shows no significant peaks, either negative or positive on the 
difference trace. This would be the case if no reaction had occurred.  
   By examination of the difference traces in Figures 3.7 and 3.8 it appears that under 
these conditions the WT enzyme is capable of both monooxygenation steps while the 
G586S mutant is competent of only the conversion of NOHA to citrulline. The G586S 
mutation seems to have uniquely disentangled the monooxygenation steps of the NOS 
reaction. 












For the purposes of this discussion it is useful to replicate the mechanism shown in the 
introduction, as it will be referred to throughout. 
 
Figure 3.9- Proposed mechanism of NOS using a Compound I active species for both 
monooxygenations. Water is lost at steps 4 and 8. 
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  Figure 3.9 shows a proposed mechanism, one of several (99, and references therein), for 
NOS. We must consider what the experiments performed here can reveal about this 
mechanism and the role of H4B.  
   Peroxide driven shunt reactions proved useful as a first line test for catalytic activity in 
the G586S mutant. However this method of testing NOS catalysis is limited. The WT 
enzyme is incapable of supporting the full catalysis of NO and citrulline from arginine by 
the peroxide shunt reaction, only from NOHA. This inability intriguingly suggests that 
the two monooxygenation steps differ from each other in some fundamental way. 
However it may be that hydrogen peroxide only offers only a poor mimicry of what is 
actually occurring in normal turnover. It could be that NOHA is a rather promiscuous 
substrate, able to react in a number of ways to produce NO. This would certainly be 
evolutionarily favourable in the construction of a robust mechanism and would explain 
NOHA’s presence as an intermediate. This peroxide shunt mechanism is fascinating but 
of limited use here, given the limitations mentioned. The results gained are insufficient 
on their own to reveal whether the G586S mutation will support complete turnover, as it 
can only provide information about the second monooxygenation step. Since the shunt 
reaction also shortcuts the reaction directly to step 8, Figure 3.9, it also reveals little of 
the activity of H4B, since it misses the electron donation from the pterin. Other 
experiments were needed. 
   Construction of the full length mutant proved to be non-trivial for various reasons and 
so other methods were sought. These other methods arguably offer greater information 
than simple turnover assays. Had the full length mutant been unable to turnover, as we 
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can now say it would have, single turnover reactions would have proved necessary to 
understand which part of the reaction the mutant was incapable of performing. 
    Single turnover assays and subsequent product analysis supported, but added to, the 
findings of the peroxide shunt reactions. Single turnover reactions have shown that the 
G586S mutant is incapable of converting arginine to NOHA. This potentially provides 
further insight into the differences between the two monooxygenation steps that have so 
often been treated as identical for ease of description.  This mutant has disentangled the 
two monooxygenation steps of NOS in a meaningful way and will now allow for further 
probing of the mechanism. 
    Limitations of OPA detection of amino acid products are several. For identification of 
amino acid products the method here described is of great use, if access to mass spec is 
limited. However for absolute quantification of amino acids there are three main 
problems. The length of time of derivitisation is key to getting reproducible data. The 
peaks for each amino acid are not all of the same broadness, requiring integration to 
determine the strength of the signal. There is also the problem of substrate and product 
remaining bound to the enzyme used in the reaction. It is therefore difficult to be 
absolutely sure of the stoichiometry of the reaction, but it is possible to identify products 
clearly. Given that, what can the single turnover reactions reveal about the NOS 
mechanism? We must pool all of the data we have on the G586S mutant. 
    Figure 3.9 shows only one of the possible mechanisms of NOS NO synthesis. While 
referring to it, it must be reconsidered in the light of the data gained here. 
    The comparison of the NOS mechanism to that of cytochrome P450s should not hide 
the fact that the reaction catalysed and the mechanism itself are unique. The production 
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of an NO radical from a stable molecule such as arginine is hard to understand, and the 
complexity of the proposed NOS mechanisms, is why NOSs are so well studied. Here the 
data provided by the G586S mutant studies will be used to shed light on the mechanism 
and the role of H4B in it.  
  The two monooxygenation steps each activate a dioxygen molecule to perform a P450-
like reaction. The P450 mechanism is widely thought to proceed via a Compound I 
intermediate, and Compound I has now been directly observed in, and found to be 
catalytically competent in, the P450 CYP119 (74). No such consensus on the active 
oxygenating species of NOS exists. Figure 3.9 shows a possible mechanism for NOS that 
uses a Compound I species for both steps of the reaction. Compound I formation in P450s 
requires single electron donation to an oxyferrous complex, followed by two protonations 
and the removal of a water molecule. The oxyferrous complex in NOS is hydrogen 
bonded to the substrate in the active site. It is likely that by interaction of the substrate 
guanidinium the oxygen on the heme will have a polarised character, with greater 
electron density on the distal oxygen. P450s lack the stabilising effect of the interaction 
and oxyferrous decay is typically faster than in NOS (101). The reduction of the 
oxyferrous complex NOS occurs with the transfer of an electron from H4B, which, while 
close enough to the heme to allow very rapid electron transfer, is a possibly 
thermodynamically uphill reaction. In P450s the transfer of an electron is usually via a 
flavin or iron-sulphur cluster. The potentially unfavourable electron transfer from pterin 
to oxyferrous complex in NOS likely results in an equilibrium disfavouring reduction of 
the heme. Step two of Figure 3.9 shows a possible way for the electron, once transferred 
from the pterin, to be locked on the heme; the protonation of the peroxo ferric species 
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complex. Protonation of the peroxo ferric complex after reduction by H4B may then be 
key to mechanism. 
   The G586S mutation stabilises two intermediates, both highlighting the role of H4B in 
the mechanism. The mutant shows a red-shifted Soret band for the oxyferrous complex 
compared to the WT enzyme and the aH4B-bound mutant. That a redox inactive pterin 
does not red-shift the spectrum of the oxyferrous complex shows that the mutant must be 
having an effect on H4Bs role as an electron donor. The mutant has an extra hydrogen in 
the active site, due to the introduced serine. It is possible that introduced hydrogen bond, 
by strengthening interaction between the dioxygen and substrate guanidinium, shifts the 
electron transfer equilibrium from the pterin to the heme. Shifting the equilibrium to the 
heme would lend a significant peroxoferric (or hydroperoxoferric) character to the 
oxyferrous complex. Intriguingly the hydroperoxoferric complex of chloroperoxidase has 
a Soret peak similarly red-shifted (101). The hydroperoxoferric complex is a very 
unstable species and at room temperature decays much faster than it forms and so is 
difficult to detect.  
The second intermediate stabilised by the G586S mutant is that observed following the 
decay of the oxyferrous species. The spectrum of this intermediate seems oddly 
undefined in its major absorbance band. This may lead to speculation that the 
intermediate is actually two species, possibly in rapid equilibrium. The intermediate 
decays with a single rate, where a mixture of species would be expected to decay with 
several rates. This intermediate forms after electron transfer from H4B. An electron 
transfer from the pterin to the oxyferrous complex would therefore form the peroxoferric 
heme complex, steps 2 and 7 of the mechanism in Figure 3.9. By protonation of the 
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peroxoferric heme complex a hydroperoxoferric heme complex would form. Some 
researchers favour the hydroperoxoferric species as the active oxygenating species of 
NOS (102). The hydroperoxoferric species may abstract a proton from the substrate, and 
form a Compound I species, as shown in Figure 3.9. The intermediate stabilised by this 
mutant could then be the peroxoferric, hydroperoxoferric or Compound I species.  
Comparison of the spectrum of this intermediate with these species as observed in other 
heme-thiolate enzymes may be productive. The previously mentioned hydroperoxoferric 
species of chloroperoxidase has a sharply defined Soret peak at 449nm, that is quite 
unlike the intermediate observed here. Compound I is a very unstable species and usually 
only observed under extreme conditions and by freeze-quenching of reactions. To have 
stabilised a Compound I to the extent that the intermediate here is stabilised, 
milliseconds, would be unlikely in the extreme. The reported UV/VIS spectra of 
Compound I (102, 74) and ES (103) species have very little definition in the 500-600nm 
region. The intermediate observed in the mutant following oxyferrous decay shares this 
lack of definition. A Compound I species observed by flash photolysis of a Compound II 
species of cytochrome P450 119 resembles the intermediate seen here in the G586S 
mutant (104). The Compound I species reported by reaction CYP119 with m-
chloroperbenzoic acid (74) has a Soret peak at ~370nm however, and is quite unlike the 
intermediate reported here, and unlike the spectrum produced by flash photolysis. 
For several reasons it seems unlikely that direct comparison of NOS spectra with those 
of other heme-thiolate enzymes will give an exact match. The active site of NOS is 
unique. In nNOS Trp409 hydrogen bonds to the heme axial cysteine. This will directly 
affect the UV/VIS spectrum (105). Most uniquely the active site of NOS has a radical 
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cation pterin hydrogen bonded to a heme propionate. Comparison within the NOS family 
may be most revealing. Recently an intermediate with a similar spectrum has been 
observed in the W188H iNOS, which mutates the hydrogen bond to the axial cysteine 
donated by the Trp409 in nNOS. The W188H intermediate resembled that presented here, 
with a Soret peak at 421nm (95). That intermediate was found to hydroxylate L-Arg, 
unlike the intermediate observed here. 
The identity of the intermediate formed by G586S nNOS during oxyferrous decay is 
therefore still an open question. However it seems likely that the intermediate stabilised 
here is the active oxygenating species and so will prove useful for future research. But it 
may be possible from the data here to deduce some of the characteristics of the active 
oxygenating species. The stabilisation of this species must be due to stabilisation of 
bound substrate by the introduced hydrogen bonds in the active site. The introduced 
serine hydroxyl group is 3.0 Å and 3.5 Å from the terminal N groups of the guanidinium 
ion of the substrate. It is also 2.7 Å from the peptide amide of Trp587. The serine 
hydroxyl can be seen then as both a hydrogen bond donor and acceptor, stabilising 
substrate binding as binding studies showed. Hydrogen bonding may be key. 
The donation of an electron from the pterin to the heme may be unfavourable and 
require the reaction of the peroxo species with a proton to hold the electron on the heme. 
The stronger hydrogen bond between the substrate and the heme bound oxygen may slow 
this proton transfer.  
 While more work needs to be done to identify the intermediate stabilised by the 
G586S mutant it is possible to offer a hypothesis explaining the observations. De Visser 
and Tan (106) have used QM/MM calculations to discover the protonation state of the 
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substrate in NOS mechanism. That work suggests that the substrate in NOS is the donor 
of the proton required in step 2 of Figure 3.9. They calculate that this neutral, 
deprotonated, substrate L-Arg is able to undergo monooxygenation while the protonated 
L-Arg would not.  The G586S mutant has an extra hydrogen bond in the active site via 
the serine hydroxyl. The introduced hydrogen bond also introduces an extra hydrogen to 
the active site. Steps 3 and 8 of the mechanism shown in Mechanism 3.1 require the 
deprotonation of the substrate. The introduced serine may be acting either to hinder 
deprotonation or actively reprotonating the substrate. The inability of the protonated L-
Arg to undergo monooxygenation would explain the increased lifespan of the 
intermediate in the mutant (it persists until decaying by a non-normal turnover 
mechanism). This would fit with the single turnover data presented here, indeed the 
G586S mutant is unable to perform the monooxygenation of L-Arg. Harder to explain is 
the apparent ability of the mutant to perform the monooxygenation of NOHA to 
citrulline, whilst still showing accumulation of the intermediate in oxyferrous decay 
experiments. As EPR experiments suggest that the G586S serine has altered the 
orientation of the bound NOHA such that it does not interact with diatomic ligands bound 
at the heme. This alteration of orientation may cause the stabilisation of the intermediate.  
It must acknowledged that it is possible the mutant is not forming citrulline in the 
single turnover reactions but some other amino acid that elutes at the same time citrulline 
under the HPLC conditions used. LC-MS may be of use in confirming whether this is the 
case. 
Despite the mutant being unable to perform the hydroxylation of L-Arg an 
intermediate with the same absorbance maximum is observed with both substrates. With 
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NOHA the intermediate appears to lead to hydroxylation and citrulline formation. This 
suggests there is a key difference between the two monooxygenations, and they have 
been disentangled for the first time. 
What then may be hypothesised about the G586S mutant? In the first 
monooxygenation step it seems likely that the mutant, via the extra proton present in the 
active site due to the introduced serine residue, encourages protonation of the arginine 
substrate. The protonated substrate is much less likely to undergo reaction. We observe 
no turnover of the mutant enzyme in single turnover reactions with arginine. The 
intermediate stabilised in this monooxygenation step may be the reactive species in 
normal turnover, stabilised by its inability to react with the protonated substrate. An 
intermediate is also observed in the second monooxygenation step with an absorbance 
maximum at 421nm, Figure 3.1. However the overall shape of the intermediate observed 
in the second monooxygenation step is somewhat different. That we observe the 
intermediate is likely due to the protonation state of the substrate again. However, single 
turnover experiments show NOHA being converted to a product with the same HPLC 
elution profile as citrulline. This can be explained if the protonated form of NOHA is able 
react with the stabilised intermediate, albeit at a decreased rate.  
 As to what the stabilised intermediate actually is, be it peroxoferric or compound II or 




Chapter four  
 



















As has been seen previously the mechanism of NOS is still hotly debated. What is known 
of the mechanism is that the final product of turnover is the ferric heme-NO complex. 
This state is thought to be the product of a rapid oxidation of a ferrous heme-NO by the 
radical pterin cation.  Ferric heme-NO is a very weakly bound complex and rapidly 
releases NO (107). However the rate of reduction of the heme, via electrons delivered 
from the reductase domain, is of a similar order as the release of NO (40). If an electron 
is delivered from the reductase domain before the pterin radical cation oxidizes the heme 
the cation will be neutralized and be unable to oxidize the heme to ferrous-NO. This 
mistimed electron delivery from the reductase domain creates, particularly in nNOS, a 
significant amount of a ferrous heme-NO complex without a radical pterin cation to 
oxidize it as electrons from the reductase domain reduce the heme (108). Ferrous-NO has 
been called a dead-end complex due to the tightness of its binding. This complex blocks 
further turnover at the active site. Furthermore, the breakdown of the ferrous heme-NO 
complex does not lead to NO release. One mechanism for removing this complex is the 
direct reaction of the ferrous heme-NO complex with a molecule of dioxygen to generate 
nitrate and ferric heme (Figure 4.1), ready for another turnover.  
 
Figure 4.1 - Decay of the dead-end complex by reaction with molecular oxygen. 
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  NOS then has one mechanism for the removal of the ferrous heme-NO complex. With 
reference to the mechanism in Figure 3.9, the initial product of NOS turnover is accepted 
to be the ferrous heme-NO complex. In normal turnover it is predicted that the ferrous 
heme-NO complex would be oxidized by the H4B radical cation. When the pterin 
cofactor is in its neutral state it is unable to pull an electron off the heme to generate the 
unstable ferric heme-NO complex. It is then, with a neutral pterin bound, that the ferrous 
heme-NO complex may be referred to as dead-end. This dead-end state is what occurs if 
an electron from the reductase domain is delivered to the heme before NO release. 
  However, it has recently been suggested that electron transfer between the pterins at the 
dimer interface could provide an alternative mechanism for degradation of the ferrous 
heme-NO complex (99). This would add a further function to the pterin, in what is 
already a unique mechanistic use of a pterin. Figure 4.2 shows the proximity of the 
pterins, with the conjugated π-systems only 13Ǻ apart, noting also the presence of two 
tryptophans which could aid in electron transfer between the pterins. If electron transfer 
is possible between the pterins, as protein electron transfer theory would suggest it is, 
then migration of the radical from one subunit’s pterin to the other could oxidise the 






Figure 4.2- The position of the pterins at the nNOS dimer interface. The lower picture, 
B, shows two tryptophans that could aid in electron transfer between the pterins. 
Distances shown in Å. (PDB 1OM4) 
 
If this electron transfer occurs between the pterins then a reaction such as shown in 




























































Mechanism 4.1- A proposed mechanism under which it would be possible for electron 
transfer between the pterins to recover enzyme function from the ferrous heme-NO 
complex with the release of NO. Mechanism discussed in text. 
 
As mechanism 4.1 shows, electron transfer between the pterins offers a route for efficient 
recovery from the ferrous-NO state that also leads to NO production, rather than nitrate. 
The mechanism shown above starts with one heme of the dimer in the ferrous state, and 
the other as the ferrous heme-NO complex. In normal turnover this would not be an 
unusual condition, it is estimated that in normal turnover conditions 70-90% of nNOS 
hemes will be in a ferrous heme-NO complex, a huge proportion if accurate (96). The 
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rate of oxygen binding to the reduced heme is very rapid. The rate of ferrous heme-NO 
complex reaction with oxygen is at least three orders of magnitude slower than that of 
oxidation of the ferrous heme by oxygen. This would tend to leave us with one heme of 
the dimer in the ferrous heme-NO complex, and the other able to catalyse normal 
turnover. This will be referred to in this work as NO-heterodimeric (FeII-NO on one 
heme, and any other state on the other). An electron from H4B will be rapidly transferred 
to the bound oxygen, forming the superoxy-ferrous species. Regardless of whether this is 
the ultimate reactive species or not the monooxygenation of arginine will occur to form 
NOHA at the relevant active site. After this reaction the dimer will contain one ferric 
heme and one ferrous-NO. It is under this situation that electron transfer between the 
pterins could allow for the recovery of the ferrous-NO heme. After this reaction one 
pterin has been left in the radical cation state. The hypothesis is that a rapid equilibrium 
will be set up such that electrons transfer rapidly between pterins. When the radical 
cation is on the pterin nearest the ferrous-NO heme it could pull an electron off the 
ferrous-NO heme, creating the ferric-NO complex. This is a very weakly bound complex, 
and NO will rapidly be released, leaving both hemes free to start another round of 
catalysis.  
  That, at least, is the simplified scheme that we have here probed by stopped flow 
reactions. The nNOSoxy domain was used to simplify matters, by removing the delivery 






The potential for electron transfer between the hemes via the pterin cofactors was tested 
by monitoring the rate of decay of the ferrous-NO complex under various heme 
occupation states.  
   The ability of the pterin cofactors to transfer electrons between themselves would have 






Careful titration with sodium dithionite was required to produce reduced nNOSoxy (L-
Arg bound), without leaving excess dithionite. Excess dithionite would affect the inter-
pterin electron transfer we were looking to observe. Figure 4.3 shows the reduction of 
nNOSoxy with dithionite, the lack of increase in absorbance at ~350nm shows there was 











nNOSoxy reduction with dithionite
Figure 4.3- Titometric reduction of nNOSoxy with sodium dithionite. Complete 
reduction was judged by final Soret peak position and flattening of the band at 650nm. 
Qualitative titration of sodium dithionite was used to ensure complete reduction, but 
without addition of excess reducing agent. 
 
NO will only bind non-transiently to the ferrous heme, with a dissociation constant of 
0.17 nM with L-Arg also bound (109). Once reduced a saturated anaerobic solution of 
NO was used to titrate NO into the protein. This titration is shown, with spectral changes 















Figure 4.4- Spectral shifts associated with the binding of NO to ferrous nNOSoxy. Note 
the characteristic absorbance of ferrous-NO at 436nm. 
 
By careful titration it was possible to create samples of nNOSoxy with differing 
proportions of ferrous-NO heme, so that at least some of the dimmers will be NO-
heterodimeric (step 1, mechanism 4.1). These samples were then reacted with an 
oxygenated buffer and the spectral changes of the reaction followed. Following reaction 
with oxygen both the ferrous-NO and ferrous hemes will be oxidised to the ferric state. 





4.3 Stopped flow 
 
As stated in the introduction to this section, the reaction of the ferrous heme and the 
ferrous-NO hemes with oxygen will occur at vastly different rates. Figure 4.5 shows the 
spectral changes associated with oxyferrous decay and ferrous-NO decay and the very 
different timescales they occur on. Both reactions also progress from different starting 
spectra. This allows probing of this mechanism as analysis of the spectra gained can be 
fitted to allow for these two separate reactions. A confirmation of the hypothesis of 
effective inter-pterin electron transfer would have been the observation of a rate of 
ferrous-NO decay in the case of NO-heterodimers different from that recorded for the 
simple reaction of ferrous-NO complex heme with oxygen. By using samples with 
different proportions of ferrous-NO:ferrous heme it was possible to create samples with 
differing amounts of NO-heterodimer. In these experiments the amount of dimers in this 
state ranged from 36 to 50%. This is based on an assumed statistical distribution of the 
NO to the hemes. It is possible, though unlikely, that NO binds either cooperatively or 
anti-cooperatively. Table 4.1 shows the assumed NO distribution in the samples. Only in 











% Heme NO bound FeII-NO/FeII-NO FeII-NO/FeII FeII/FeII 
0 0 0 100 
24 6 36 58 
32 10 44 46 
47 22 50 28 
71 50 41 9 
100 100 0 0 
 
Table 4.1- Showing the simple statistical distributions assumed in the experiments of 
ferrous-NO decay. If there is cooperativity or anti-cooperativity then the distribution of 







Figure 4.5 - Representative spectra for various stopped flow reactions. A) shows the 
spectral change on reaction of ferrous nNOS with O2. In A can be seen the oxyferrous 
complex decaying to leave ferric heme. B) shows the reaction of FeII-NO nNOS (with 
natural pterin cofactor H4B) with O2. The Fe
II-NO reacts with oxygen to leave ferric 
heme and nitrate. C) shows the reaction of FeII-NO nNOS (with inactive pterin cofactor 
aH4B) with oxygen. The Fe
II-NO reacts with oxygen to leave ferric heme and nitrate. D) 
shows the reaction of an nNOS sample with 47% of its hemes in the FeII-NO state, the 
other hemes are in the FeII state at the start of the reaction. Here two reactions occur. FeII-
NO reacts with oxygen to leave ferric heme and nitrate. The FeII hemes react with oxygen 
to form the oxyferrous species. The oxyferrous species decays to leave the ferric heme. 
All reactions were carried out at 25˚C, against air saturated buffer (~200µM O2). 
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Figure 4.6 - Recorded and fit data at 436nm for: A) Decay of the oxyferrous complex 
formed by stopped flow reaction of reduced enzyme with oxygen, B) Decay of the 
ferrous-NO complex in protein with H4B bound and all hemes in the ferrous-NO state, C) 
Decay of the ferrous-NO complex in protein with aH4B bound and all hemes in the 
ferrous-NO state, D) Decay of the ferrous-NO complex in a protein (H4B bound) sample 
with 47% NO occupation of heme. Rates from these calculations can be seen in table 4.2. 




For any proportion of heme in the ferrous-NO state the rates observed fit well to a model 
of oxyferrous to ferric, and ferrous-NO to ferric, see table 4.2, using Pro-Kineticist 4.21 
software (Applied Photophysics), Reactions 1 and 2. Under the conditions used here the 
rate of oxyferrous formation, k1, was too rapid to be detected.  
 
Reaction 1- The observable steps in stopped flow reaction of reduced nNOS with 
oxygen. k1 is the rate of oxyferrous formation. k2 is the rate of ferric heme formation, the 
intermediate steps being unobserved in this experiment, this occurs at the same rate as the 
formation of the pterin radical. 
  
Reaction 2- The known pathway for ferrous-NO decay by reaction with molecular 
oxygen. k3 is the rate of ferric heme formation by this reaction.  
 
 Ferrous-NO decay was unaffected by whether the dimer partner heme was not in the 
ferrous-NO state, table 4.2. We observed no evidence of inter-pterin electron transfer. 






Proportion of ferrous heme 
NO bound 
Oxyferrous>Ferric k2 
Rate (s-1)           (±Errors) 
Ferrous heme-NO>Ferric k3 
Rate (s-1)             (±Errors) 
0 48.1                     (0.4) - 
0.24 35.0                     (0.3) 0.12                     (0.01) 
0.32 35.1                     (0.5) 0.12                     (0.01) 
0.47 34.0                     (0.4) 0.12                     (0.01) 
0.71 29.4                     (0.4) 0.12                     (0.01)        
1 - 0.12                     (0.01) 
 
 
Table 4.2- Rates of reaction for oxyferrous decay and ferrous-NO decay measured by 
stopped flow reaction at 25˚C. No change of rate for ferrous heme-NO decay was 
measured in rate for any proportion of the sample in the ferrous-NO state. The rate of 
oxyferrous decay was ~32s-1 for all experiments. The models were fit to an A>B, C>B 
reaction (both the oxyferrous and ferrous heme-NO complex decay to the ferric state), 
except the first and last rows which were A>B reactions as they contained only one heme 
state to decay to ferric. These results match well with other studies (110). 
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Figure 4.7- Comparing the decay data gained for different samples. After the first few 
seconds of reaction almost all the oxyferrous species will have decayed. This should 
leave curves of similar shape if there is no inter-pterin electron transfer, which is what we 
observed. 
 
Can the pterins of an nNOSoxy dimer transfer electrons effectively between themselves? 











Using simple statistical distributions it was trivial to predict what proportion of dimers 
were in the NO-heterodimeric state. While it would be possible to use any of these 
proportions to test the inter-pterin electron transfer a variety was used for a thorough 
examination. Confirmation of our titrations, of the amount of NO bound, was calculated 
graphically, see Figure 4.7. The amplitudes used in this graph were calculated from the 
reduced protein sample compared to the maximum absorbtion peaks of the two species. 
The more NO was bound, the less oxyferrous heme should have been generated, and that 
is what we see in Figure 4.8. 













Proportion of Heme NO bound
Figure 4.8 - How amplitude at 426nm (oxyferrous) and 436nm (ferrous heme-NO) 
change with the proportion of NO bound to the ferrous heme. These amplitudes represent 
the difference in absorbance at these wavelengths compared to the reduced protein 





As we see no inter-pterin electron transfer we can say it is certainly not because we 
miscalculated the amount of ferrous heme-NO complexes.  
   Having discussed why inter-pterin electron transfer is likely how then can we account 
for not observing it? There are two possibilities; it is occurring and we have not observed 
it or it is not occurring. Here we will discuss which is the more likely scenario. 
   Mechanism 4.1 shows what we predicted would happen in a special circumstance. Here 
we created those special circumstances, under a range of conditions. At which stage of 
the proposed mechanism does the experimental data differ from prediction?  We certainly 
formed at least some NO-heterodimers (dimers with only one of their hemes in the 
ferrous-NO state) as shown in step one. The formation of the oxyferrous complex occurs 
at 25°C at ~180 s-1 while ferrous heme-NO decays at a 0.12 s-1, so step two is certainly 
likely to form in the majority of NO-heterodimers. Step three is the donation of an 
electron from the pterin to form the radical pterin cation (111). This is the accepted 
mechanism, and occurs at ~32 s-1. Between steps 3 and 4 of the mechanism as shown in 
mechanism 4.1 occurs the monooxygenation of the substrate in normal turnover. It is 
assumed it occurs in these experiments. It is at this point that electron transfer was 
expected to occur between the pterins, leading to equilibrium, and allowing the release of 
NO. However the rate of ferrous heme-NO decay was the same in samples completely in 
the ferrous-NO state, and those in the NO-heterodimeric state, table 4.1. 
  13Å is within what is considered a reasonable distance for efficient electron transfer. 
What efficient means depends on whom one asks. It is generally held to be in the range of 
hundreds or thousands of electron transfers per second. Since the rate of ferrous heme-
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NO complex decay is here measured at 0.12 s-1 it would seem that electron transfer is not 
occurring between the pterins.  
  The most reasonable explanation for not monitoring inter-pterin electron transfer is then 
that it does not occur under these conditions. The role of H4B must therefore be 
reconsidered in the possibility that it is possible that the pterin radical is kinetically 
stabilised by undergoing some chemical transformation, for example deprotonation to 
form the neutral radical H3B. Proton transfer from the pterin to the heme, as has been 


















































Mechanism 4.2- A proposed mechanism for the stopped flow reactions performed with 
NO-heterodimers showing proton transfer coupled with electron transfer from the pterin. 
Here electron transfer between the pterins would be unlikely as migration of the radical 
between pterins would require the formation of the anion radical form of H4B, which 
would be heavily disfavoured. 
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A further possibility is that the widely accepted mechanism of the H4B radical cation 
removing an electron from the ferrous heme-NO complex to induce NO release may not 
actually be occurring (84).  
   Pterin proton transfer is far more likely. There is already a putative proton transfer 
pathway from the pterin to the heme iron, Figure 4.9. 
 
Figure 4.9 - The putative proton transfer pathway, via red hydrogen bonds, between H4B 
and heme-oxy species (here peroxo ferric). The hydrogen on N5 is solvent accessible 
(100). 
 
On the donation of an electron from H4B there will be a shift in the hydrogen bond 
between N3 of the pterin and the heme propionate, towards the heme. The hydrogen on 
N5 is solvent accessible, and there is therefore a potential pathway through which solvent 
derived protons may be transferred to the heme oxy species.  
  The evidence presented in this chapter does not prove the putative proton donor role of 
H4B. However there is no theoretical reason why electron transfer between pterins should 
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not occur. No evidence for electron transfer between the pterins has been observed. 
Electron transfer would be unlikely to occur if H4B is also a proton donor as it would 

























































H4B is an essential cofactor for several vital enzymes. It plays a key role in production of 
the neurotransmitters L-DOPA by tyrosine-3-hydroxylase and 5-hydoxytryptophan by 
tryptophan-5-hydroxylase (68). In this chapter, however, the role of H4B in the 
mechanism of NOS will be addressed via reference to several novel analogues of H4B.  
    The importance of the H4B binding site as a drug target has only recently become 
clear. Mutations of the enzymes responsible for the synthesis of H4B are thought to be the 
causal factor in diseases showing a severe depletion of serotonin and dopamine, such as 
hyperphenylalaninemia (112). Synthesis of H4B from GTP requires the enzymes GTP 
cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase and sepiapterin reductase. For 
H4B to be regenerated from the dihydro-form requires pterin-4a-carbinolamine 
dehydratase and dihydropteridine reductase (113). A harmful mutation is possible in any 
of these enzymes and the effects of H4B deficiency can be severe. The use of drugs to 
treat such a deficiency would be of great value, however the unstable nature of H4B 
makes it of limited use as a drug, particularly if the underlying problem is in the enzymes 
required for regeneration. Treatments of 4-20 mg/kg of H4B have been used in 
phenylketoneuria, and the cost is seen as prohibitive (114).  
  Previous work on analogues of tetrahydrobiopterin have tended to focus on them as 
possible inhibitors (107). Aside from one previously published structure, which is 
reexamined here, the only commonly known pterin analogue activator is the C5 methyl 




Figure 5.1 - The 5-methyl analogue of H4B. 
 
  With all three mammalian isoforms of NOS requiring H4B for catalysis and the vital 
nature of NO in the body it is clear that H4B, or a compound mimicking its activity, could 
be of medical use. H4B treatment for high blood pressure is effective, certainly in rats 
(115). Further work is necessary on the medical use of H4B, but what is clear is the need 
for a more suitable delivery system for H4B or a more stable analogue of H4B. 
   Aside from use as a drug, an analogue capable of supporting NO production by NOS 
would be useful in elucidating the role of H4B in the mechanism. As described in the 
introduction to this thesis the role of H4B is subtle and still not entirely clear. We know 
that it acts as both an electron donor and acceptor, and forms a strongly oxidising radical. 
Debate hinges on whether H4B is also a proton donor, as some have suggested (116). By 
testing a range of analogues of H4B for activity it was hoped that a structure/function 






5.1.1 Aims  
 
With a potent inhibitor for NOS already known that targets the pterin binding site, aH4B, 
it is in the search for activators that most research is focused. 
 Here dihydropterines blocked at the C7 position (Figure 5.2 for pterin numbering 
system) were trialed as active analogues, with hopes that the blocking would prevent 
reoxidation. In H4B it is possible to get oxidation across the 6-7 bond forming an inactive 
dihydropterine form. By adding substituents to the C7 position it is possible to block this 
reaction. This blocking was performed to try and stabilize these analogues compared to 




5.2 Turnover assays 
 
Analogues were synthesised by Craig McInnes at Strathclyde University, Figure 5.2. 





                                                
                                               
Figure 5.2- These analogues were found to give at least some activity in vitro, or to act 
as inhibitors. Shown at the top is pteridine with the ring numbering system used here to 
describe analogue structure.  
 
All analogues were screened for activity by turnover assay (section 2.8) where NO 
production is detected by the conversion of oxyhemoglobin to methemoglobin, and the 
measurement of the spectral shift at 401nm that conversion causes. Those analogues with 
measurable activities were taken forward for more in depth analysis. Table 5.1 shows the 




Compound Rate            (min-1) 
                   (±Errors) 
H4B ~18                    (1.1) 
WSG1060 8.2                     (0.3)                      
WSG1007 2.8                     (0.4) 
WSG1010 1.3                     (0.4) 
WSG1002 11.2                   (0.9) 
NMe1002 0.0                     (0.0) 
WSG1017 Inhibitor* 
Table 5.1- The rate of activity derived from assays of the pterins with nNOS. All 
compounds were screened at 20µM, except WSG1002 where the vmax is given. * See text 
for discussion of WSG1017. 
 
As can be seen from Table 5.1 the rates of turnover supported by the analogues varies 
greatly, at least at 20µM concentrations. Previous work on WSG1002 had shown it to 
have a Kd of 151µM (117). However, in this study analogues were being sought that 
could compete with H4B in both binding affinity and activity so concentrations of 20µM 
were used in initial screening as a maximal concentration. 





























Figure 5.3- The activity curves derived for WSG1007 and WSG1060, fitted to the 
Michaelis equation by Origin 8.1 (OriginLab Corporation).  
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  After screening, two analogues, WSG1060 and WSG1007, were chosen for further 
study. These two 6,7-cyclized pterins were thought the most interesting structurally, and 
being similar in structure would allow for greater structure/function analysis. Figure 5.3 
shows how activity for these two analogues varies with concentration. This allowed for 
the calculation of Kd and Vmax. These are shown in table 5.2, as well as those for 
WSG1002. 
 
Pterin Kd  (µM)              (±Errors) 
 
Rate of NO production as 
% of  H4B 
H4B <1                            100 
WSG1007 5.6                           (1.0) 25 
WSG1060 7.4                           (1.6) 55 
 
 
Table 5.2- Showing the Kds for the two most active analogues, derived from fitting of 
activity curves to Michaelis equation by Origin 8.1 (OriginLab Corporation). Kd is used 
rather than Km as the pterin is not the substrate of the enzyme, but a cofactor. 
 
These novel, alloxazine-like, analogues (WSG1007 and WSG1060) had binding affinities 
similar to H4B. However the rates at which they support catalysis are significantly lower. 
This was mechanistically interesting and so further studies were performed to ascertain 
whether the difference in catalytic rate was related to the ability of the analogues to 
donate electrons, a vital mechanistic step.  
 
5.3 Stopped flow 
 
When molecular oxygen is reacted with the reduced heme of NOS an oxy-ferrous species 
forms rapidly. This has a characteristic Soret peak at 426nm. With the donation of an 
electron from the pterin cofactor this species decays to the ferric heme. With a bound 
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substrate and H4B this would lead to a normal monooxygenation. With aH4B, an inactive 
pterin, this electron donation cannot occur and there is no turnover, see Figure 5.4, and 
the rate of oxyferrous decay is significantly slower. 





















Figure 5.4- Showing the steps in stopped flow monitoring of oxyferrous decay, and 
associated rate, for H4B and an inactive analogue of H4B, aH4B.     
 
Figure 5.5 shows the decay of the oxy-ferrous species as followed by stopped flow 
spectrophotometry. This allows for a calculation of the rate of decay of the oxy-ferrous 
species, and therefore the rate of electron donation from the analogue. 
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Figure 5.5- This Figure shows the spectral changes involved in the decay of the 
oxyferrous species in nNOS with H4B. These changes allow the rate of electron donation 
from H4B to be calculated. The reaction allows the rate of electron transfer from pterin 
analogues to be measured.    
 
These rates were calculated for the five pterins, shown in table 5.3, as calculated by Pro-
Kineticist 4.21, Applied Photophysics, software from the total spectra collected over 1s. 
Using a simple A>B (Oxyferrous to ferric) model rates of decay were arrived at. The rate 
of decay of the oxyferrous species being equal to the rate of donation of an electron from 
the pterin it gives a measure of the redox activity of the analogues. The rates for H4B and 






Pterin FeII-O2 to Fe
III (s-1)                (±Errors) 
WSG1002 25.2                                      (0.3) 
WSG1007 24.5                                      (0.2) 
WSG1060 24.7                                      (0.2) 
aH4B <1s
-1 
H4B 27.8                                      (0.2) 
              
Table 5.3- The rate of oxyferrous decay, and therefore the rate of electron donation from 
the pterin, measured at 10°C and over the course of a second after mixing the reduced 
protein with an oxygenated buffer. 
 
As table 5.3 makes clear all analogues tested were able to donate electrons to the heme at 
a rate similar to H4B. The rate of oxy-ferrous decay with aH4B was too slow to accurately 
measure over 1s, but over a longer timescale agreed well with the previously ascertained 
rate, 0.06s-1. The rates of all three novel analogues tested were similar to each other and 
H4B. This is somewhat puzzling as, table 5.2 shows, these analogues supported turnover 
of the enzyme at significantly different rate. It is likely that the difference in turnover 
rates is due to differences in the ability of these analogues to support the NOS dimer. 
This will be addressed further in the discussion.  
 
5.4 Analogue decay 
 
Working with these compounds it became clear that some of these blocked 
dihydropterine analogues of H4B had problems of stability. When working with H4B in 
vitro it is important to add a reducing agent such as DTT to the H4B solution to stop 
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oxidation to the inactive dihydro-form (118). This is why DTT was a standard addition to 
the assays. With DTT added a solution of H4B, kept on ice, maintains its activity for 
several hours. This was not neccessarily the case with these analogues. 
   All analogues were judged pure by NMR and HPLC following preparation (57). They 
were then exposed to a high vacuum to produce a stable solid and kept at -80°C. It 
became readily apparent that some change was occurring once the analogues were placed 
in solution, strong changes in colour occurred. It also became apparent that this change 
was related to a reduction in the ability of the analogues to support turnover. After 1hr in 
solution WSG1060 had lost approximately 40% of its activity. This occurred in the 
presence of DTT, and in aerobic or anaerobic solutions. Ascorbic acid was also tried to 
limit or recover activity in the analogues, but was ineffective. The following spectra show 
the change in absorbance of the analogues over time. 
 
Figure 5.6- The spectral change recorded for a 5mM solution of H4B, aerobically and 











































Figure 5.7- The spectral changes recorded, anaerobically, for WSG1002, WSG1007, and 
WSG1060. Each line represents 5 minutes. 
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Figure 5.8- The spectral changes recorded for WSG1060 aerobically. Each line 


















Figure 5.9- Spectral changes recorded for the colourful solution product of WSG1060 
after the addition of sodium dithionite. 
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The formation of this broad peak at 417nm, Figures 5.7 and 5.8, in WSG1060 can be 
reversed by addition of dithionite. However the reduced ‘colourful product’ of WSG1060 
decay, while losing its absorbance at 417nm, does not recover its activity. There would 
appear to be no simple way to undo whatever reaction is occurring on WSG1060 entering 
solution. 
   Interestingly a similar spectrum has been reported for another analogue of H4B, 6-
formyl-7,8-dihydropterin, Figure 5.10 (119). This may suggest the rearrangement of 
bonds that occurs when WSG1060 goes into solution. 
                                       
 
Figure 5.10- The structure of a pterin analogue, 6-formyl-7,8-dihydropterin, with a 
UV/VIS spectrum very similar to the colourful WSG1060 product. 
 
If a direct comparison is useful it would suggest that a double bond has formed between 
the N5 and C6 of WSG1060, forming the conjugated π-system likely responsible for the 
absorbance in the 417nm region. However, sodium dithionite would not normally be able 
to reduce a double bond. It would also require an oxidizing agent to perform this double 
bond formation, something lacking in anaerobic conditions.  It is possible that we are 
observing a keto-enol tautomerisation. However this would only be possible in the case 





(With Laura Campbell, University of Edinburgh) 
 
The binding mode of the pterin cofactor is an important factor in the electron transfer role 
of the pterin. Crystallographic study in therefore vital in the design of new analogues. For 
the analogues here presented the determination of the crystal structure of the nNOSoxy 
protein with analogue bound was attempted. The rearrangement of the residues which 
compose the pterin binding site would presumably be altered by the large extensions on 
the analogues. A crystal structure with an analogue would be useful in revealing whether 
the analogues disrupt the dimer interface. 
                    
Figure 5.11 - Crystals of digested nNOSoxy with WSG1060. 
   The crystallographic approach was similar to that previously described for the G586S 
mutant nNOSoxy. The conditions which provided crystals were as follows: 0.1 M MES 
(pH 5.8/6.0), 22-24% PEG 3350, 0.2 M ammonium acetate, 25 mM L-Arg, 35 mM SDS, 
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5 mM GSH, 2% isopropanol. Crystal growth was attempted at 4°C and 17°C. Crystals 
became apparent after 2 days. 
      Crystals were readily grown with WSG1060 at 17°C, under most of the conditions 
trialled, as seen in Figures 5.11 and 5.12.  
 
         
Figure 5.12- The shape of the crystals gained with WSG1060 was broadly similar to that 
of nNOSoxy with H4B. 
 
The crystals achieved by this method were similar in shape and colour to those previously 
gained for the WT oxygenase domain with H4B. The crystals grown here were small, 
~10µm in size. This made collection of single crystals difficult. The largest crystals were 
however collected and prepared for the data collection. The largest crystals shattered on 
freezing. Of the crystals that survived freezing none diffracted significantly. In view of 
the lack of stability of the analogues in water it seems unlikely that useful analogue-























The binding site for H4B is at the dimer interface of the NOS oxygenase domains (PDB 
1OM4). The binding pocket can be seen in Figure 5.13 and shows the distal portion of the 




Figure 5.13 - The residues defining the distal portion of the pterin binding site. Both 
subunits supply several residues to the binding pocket. Not that both subunits are stongly 
present in this portion of the binding pocket. (PDB 1OM4, unpublished paper)  
Subunit 1 = Trp306, Trp676, Phe691, His692, and Glu694 
Subunit 2  = Ser334, Met336 
 
This distal portion of the binding site offers more space for modification than does the 
heme-proximal portion. The heme proximal portion is also the ‘business-end’ of the 
molecule, involved in electron, and according to some researchers proton, transfer. This 
portion of the pterin must be held in the correct orientation to allow electron transfer, and 
must maintain a hydrogen bond to the heme propionate. Extension at these positions is 
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not well tolerated, even a methyl addition at the C2 position, shown here in the N-methyl 
analogue (NME1002), abolishes activity. The distal portion contains the sites of the 
interactions between the pterin and both subunits of the dimer. Dimerisation is vital to the 
activity of the enzyme as electrons pass from one subunit of the dimer to the other (120). 
As the modifications of the analogues here described are mainly at the C6 and C7 
positions, possibly involved in dimerisation, we must consider the role of the analogues 
on dimerisation. First let us consider what can be learned from a structure/function 
analysis of the analogues we have tested. 
 
5.7 Structure/Function Relationship 
 
The first comparison to be made should be between the analogues WSG1007 and 
WSG1060, the 6,7 cyclized pterin and the 6,7 cyclo ketone pterin respectively, and 
WSG1002, the 6-acyl, 7,7 dimethyl pterin, and H4B. Figure 5.2 compares these 
structures. 
       The Kds for WSG1007, WSG1060, WSG1002 and H4B are 5.6µM, 7.4 µM, 151Μm 
and ~1µM respectively. This shows that extension at the C7 position is well tolerated but 
will decrease binding affinity. Interestingly the larger extensions of the 6,7 cyclized 
pterins decrease binding affinity less than does the relatively small 7,7 dimethyl 
extension. This is difficult to explain. It is possible that the introduced ring structure, 
easily accommodated spatially, may favour binding of these analogues in the correct 
orientation by a stacking interaction with Trp676, Figure 5.12. The possible stacking 
interaction with Trp676 may also lead to increased dimer stabilisation. Without a crystal 
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structure of the protein with these analogues bound it is difficult to discuss binding modes 
or the rearrangement of residues necessary to allow their binding.  
   The keto groups of WSG1002 and WSG1060 might mimic a hydroxyl group on the C6 
extension of H4B. In iNOS the dihydroxypropyl side chain interacts with Ser104 or 
Phe462, depending on the diastereomer form of the pterin (95). If this keto oxygen is 
mimicking an interaction of the normal dihydroxypropyl group it does not give an 
increase of binding affinity here. The keto group does seem to increase the activity of the 
analogues however. One problem with discussing the binding affinity of these analogues 
has already been mentioned. Using an activity assay to assess the binding of analogues 
requires the analogues to still be active. As has been shown, on being placed in solution 
there is a rapid reaction forming a colourful, inactive, product. While efforts were made 
to work quickly with the analogues by necessity some time passed. This makes it 
impossible to accurately and absolutely gauge the concentration of active analogue 
present in the assay mix. The Vmax of the analogues may be a better measure for analysis. 
   From the structures in Figure 5.2 we can clearly rank the analogues in terms of 
maximum turnover rate. H4B has a Vmax of ~18 min
-1. The 6-acyl WSG1002, with a keto 
group in place of the first hydroxyl of H4B achieves a Vmax of approximately 11 min
-1. 
The bulkier 6,7 cyclo-keto pterin, WSG1060, which shares this corresponding keto 
oxygen achieves a rate of 9 min-1. The 6,7 cyclized pterin, WSG1007, lacks this keto 
group and has a Vmax of approximately 7 min
-1. From these Figures we can suggest a role 
for an oxygen on the C6 extension of the pterin in maintaining the correct binding mode 
of the pterin. However, its presence is not an absolute requirement. Intriguingly having 
only a methyl group at the C6 position reduces activity greatly (WSG1010). 
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   WSG1017 has the largest C6 extension of any of the analogues here tested. No activity 
was recorded of this analogue, with its chlorophenylacyl side chain. However it did act as 
a competitive inhibitor against H4B. This suggests it binds in the pterin binding site, but 
probably not in the correct orientation. This may point to a maximum C6 extension size 
for active analogues. 
  Stopped flow data on oxy-ferrous decay shows no significant difference in the rate of 
electron transfer from the analogues to the heme. This could have been the source of the 
difference in turnover rates, though unlikely as the rate of turnover is closely linked to the 
rate of electron delivery from the reductase domain (121). The slower rates of turnover 
could have been explained if the rate of electron transfer was sufficiently slow to allow 
build up of a dead end complex. This is not the case. How then can we explain the 
difference in turnover rate between these pterins? 
  It is here that we must discuss dimerisation. Monomeric NOS is unable to produce NO 
as the electrons required for turnover are derived from the reductase domain of the dimer 
partner (122). An active H4B analogue must be able to donate and accept electrons at a 
suitable rate, but must also stabilise the dimer.  
  The analogues tested by stopped flow, which all conserve the basic pterin structure, are 
able to donate electrons at a rate similar to H4B. The rates are marginally slower, 
suggesting a slight increase in the distance of the analogue from the heme propionate 
compared to H4B, as electron transfer rate is effected by distance. The slower rate of 
electron transfer may also be due to changes in the electronic potentials of the pterin 
induced by the modifications. However this work makes it seem likely that any analogue 
that conserves this basic structure and bind in approximately the correct orientation will 
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be able to fulfill the requirement of electron donor. However the analogues tested support 
NO production at markedly different rates. One possibility is that the alterations at the C6 
and C7 positions are interfering with dimerisation of the enzyme.  
   With reference to the structures in Figure 5.2, we can see that these blocked 
dihydropterines are bulkier in the heme-distal portion than H4B. Figure 5.13 shows the 
residues that form the distal pocket of the pterin binding site are contributed by both 
partners of the dimer. The extra size of the analogues in the distal portion could disrupt 
dimerisation by some extent, probably by displacing Trp676, Phe691, and His692. If the 
first hydroxyl of the sidechain of H4B contributes to dimerisation by formation of a 
hydrogen bond, then the keto oxygen of WSG1060 and WSG1007 may also be able to. 
This would tend to stabilise the dimer. However the extra bulk of the analogues could 
disrupt the dimer. This could well explain the difference in turnover rates. WSG1007, the 
6,7 cyclized analogue, lacks a corresponding oxygen to the H4B hydroxyl. Its turnover 
rate is lower than WSG1060, giving further evidence to support a stabilising role for the 
keto oxygen. With the binding of these analogues there is likely to be some structural 
rearrangement of the residues of the pterin binding site. Without a crystal structure it is 
hard to judge how great this rearrangement is likely to be. However if the analogues are 
disrupting dimerisation it may be hard to gain a crystal structure as all structures of the 
NOS oxygenase domain so far gained have been of the dimer. Disruption of the dimer 
may have led to the formation of the smaller crystals gained here. It may also have 
caused heterogeneity in the crystals and blocked diffraction. Further work needs to be 
down to ascertain the effect of these analogues on dimerisation. 
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   Another remaining possibility is that the analogues are less effective oxidising agents. 
The ability of the radical cation to pull an electron off the heme is vital in the release of 
NO as it converts the ‘dead-end’ ferrous heme-NO complex to the deeply unstable ferric 
heme-NO complex. Monitoring turnover assays for the build up of the ferrous heme-NO 
complex may shed light on this possibility. 
  The final possibility hinges on the hypothetical role of H4B as a proton donor. A 
hydrogen bond network, linking N3 of H4B to the substrate could allow passage of a 
proton. This is a common enough motif in biological mechanisms to be feasible. 
Unfortunately the analogues here tested reveal little about this possibility. Computer 
models of the analogues reveal no great difference in the likelihood of the N3 amino 
group to give up a proton, compared to H4B. Analogue design focused on altering the 

























NO is a vital and versatile biological molecule. The mechanism by which NO is produced 
by NOS is thought to follow the general mechanism for cytochromes P450. However 
NOSs are unique in their cofactors and the reaction they catalyse. The mechanism has 
been closely studied but the active oxygenating species has not been identified. The role 
of the pterin cofactor of NOS, tetrahydrobiopterin, is subtle and unique. It is so subtle and 
 161 
unique that doubt still reigns over its exact role in the mechanism. The main aim of this 
project has been to further our knowledge of the role of H4B in the NOS mechanism.  
What has been uncovered about the role of this interesting pterin has clarified some 
matters but also pointed to further work that must be done. 
 
   The G596S mutant stabilises an intermediate formed by electron donation from H4B to 
the oxyferrous complex capable of the monooxygenation of NOHA to produce NO, but 
incapable of the hydroxylation of L-Arg. This is the first time that the two 
monooxygenations have been separated in reactions mimicking normal turnover. There 
are three possibilities to explain this result: the two steps of the NOS mechanism are 
different in their active species, or the mutant stabilises L-Arg to such an extent that that 
the active species decays before it has a chance to react, or that the stabilised intermediate 
is not the active species of normal catalysis but one still capable of the second 
monooxygentation. This is the first NOS mutant reported that can catalyse only one of 
the two monoxygenations. This is not sufficient evidence to suggest that the two 
monooxygenations proceed via different intermediates as the reactivity of the substrates 
may be different. Stabilisation of L-Arg, probably by protonation from the introduced 
serine hydroxyl, is supported by DFT calculations showing the protonated substrate to be 
less reactive. The final possibility is that the intermediate stabilised here is not the 
reactive species. Spectral changes in the mutant oxyferrous complex hint at that electron 
transfer from the pterin is favoured in this mutant compared to the WT enzyme. It may be 
that by stabilisation of the active species, if it is a Compound I, that an extra electron is 
pulled from the pterin to the heme to form a Compound II. It is then possible that NOHA 
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is able to react with this Compound II, while L-Arg is not. Further work must be done to 
confirm which of these hypothesises is correct. 
   Further work must be undertaken to ascertain what this mutation can tell us about the 
role of H4B in NO synthesis. Further work should be done to identify the stabilised 
intermediate. This could be achieved by double mixed stopped flow reactions with 
various oxidising and reducing agents to probe the reductive potential of the intermediate. 
Freeze quenching EPR experiments would allow us to test whether the stabilised 
intermediate is the product of a second electron being pulled off the pterin, forming a 
Compound II species, Fe(IV)=O.   
 
  H4B is a very complex molecule with redox states ranging from biopterin to 
dihydrobiopterin to tetrahydrobiopterin and stabilised radical states as seen in the NOS 
mechanism. It is used by a range of enzymes for a range of reactions. Only in NOS does 
it play a sublime role as oxidising and reducing agent over the course of a single 
turnover. With these roles for the pterin cofactor in mind, and in some cases still poorly 
understood, we sought to test a further possible role.  
  The ferrous heme-NO complex is considered a dead end complex. In normal turnover it 
is thought that the radical pterin cation oxidises the heme to the less stable ferric heme-
NO complex, and so releases NO at the end of each turnover. However if an electron 
from the reductase domain is delivered before this oxidation by H4B, then the dead-end 
ferrous heme-NO complex will accumulate. Since H4B is considered to rescue the 
enzyme from this dead end complex in normal turnover in this way we sought to test 
whether electron transfer between the pterins would allow it to rescue ferrous heme-NO 
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build up caused by premature reduction from the reductase domain.  The H4B molecules 
in the nNOS dimer are bound 13Å apart. This distance is within the range of what has 
previously been designated as allowed for efficient electron transfer in a protein medium. 
Two identical molecules within this distance should set up a rapid equilibrium if one is 
oxidised, as electrons will transfer between them. The possibility of electron transfer 
between the pterins in the nNOS enzyme offered a route of recovery for the enzyme from 
the dead-end ferrous heme-NO complex. This was probed by stopped-flow reactions 
involving NO-heterodimers of the enzyme with only one of the hemes in the dimer in the 
ferrous heme-NO complex. Monitoring decay rates for the ferrous heme-NO complex 
found no difference between the rate of these NO-heterodimers, and dimers with both 
hemes in the ferrous heme-NO complex. This suggests either no electron transfer 
between the pterins, or electron transfer between the pterins is unable to rescue a heme 
from the dead-end complex.  There is no easy explanation as to why there would not be 
electron transfer between the pterins, but no easy way of absolutely confirming it. One 
tantalising possibility is that the pterins role in the mechanism also involves proton 
transfer, which would slow down interpterin electron transfer. The hypothesis tested by 
these experiments hinged on the presumed role of H4B as the oxidising agent in normal 
turnover of the ferrous heme-NO complex. If this assumption is incorrect it would allow 
for electron transfer to occur but the migrated radical cation would be unable to rescue 
the dead-end complex. If H4B is not the oxidising agent of the ferrous heme-NO complex 




  H4B is so valuable a molecule due to its role in the synthesis of NO that its binding site 
represents a major drug target. NO is involved in vital physiological processes ranging 
from immune responses to blood vessel relaxation to angiogenesis. Antibiotics, erectile 
dysfunction and cancer bring pharmacology companies billions. The search for H4B 
analogues that are functional in NO synthesis but also more stable and druggable is an 
important one. Most importantly H4B analogues will allow the probing of the role of H4B 
in NOS mechanism.  
  The extension with two hydroxyls on the C6 position of H4B is not functionally 
necessary. All analogues that showed activity were altered in this position. More work is 
required to probe the role of substituents on this part of the molecule however. It may 
play some role in determining the tightness of pterin binding. 
 While none of the analogues tested in this work seem suitable as drugs, lacking the 
stability we sought, the binding and catalytic features of the molecules have been tested. 
A large range of extensions are possible in the C6 and C7 positions that allow binding of 
the pterin in the correct orientation and give activity. A six membered ring at the C6 and 
C7 position gives analogues with Kds <10µM, showing the volume of extensions 
allowable in this position. An inhibitor of NOS activity with a very large and mobile 
chlorophenyl side chain on the six position hints at the upper limit for extension. 
Blocking at the C6 and C7 positions to the dihydropterine form does not abolish activity 
of these analogues. This offers scope for further analogue design that may lead to 
druggable compounds as trapping in an active dihydropterine form should remove the 
need for analogues to be regenerated by dihydropterine reductase. 
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  Adding a carbonyl group next to the pterin does not affect the ability of the pterin to 
donate electrons. This suggests that the electronic configuration of the pterin will be able 
to withstand additions next to the pterin and still fulfil its redox functions.   
  The decay of the several of the analogues to an inactive form in solution requires further 
study if progress is to be made in the search for druggable active pterins. The is potential 
in NMR studies of the analogues in solution to uncover in what way they are becoming 
inactive. 
  For the analogues to be of further use in unravelling the role of H4B more work must be 
done. The binding mode of the analogues must be probed. The electrostatic interaction of 
the analogues with the enzyme must also be probed. To allow this a crystal structure of 
NOS with the analogue bound would be most useful. The work on crystallisation should 
hopefully prove trivial with the basis of work here presented.  The key question as yet 
unanswered about these analogues is why, when they all transfer electrons at rates 
comparable to tetrahydrobiopterin, the rates of enzyme turnover are significantly slower. 
That extensions to the C6 and C7 of the pterin may in some way be impairing 




In summary the results in this thesis have shown that: 
-The two steps of NOS catalysis can be disentangled by mutagenesis of the active site 
residues. 
-That interpterin electron transfer does not occur during the oxygen activation process. 
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-That large substituents can be added to the C6 and C7 positions of pterin analogues 
while retaining activity. 
  All of these results offer novel insights into the role of H4B in NOS and point to future 
areas of investigation. 
 







































1- E. Faassen, and A. F. Vanin 
 Radicals for life: the various forms of nitric oxide (2007) 
 Published by Elsevier, Netherlands 
2-Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. 
Proc Natl Acad Sci U S A.  84:9265-9. (1987) 
3- Furchgott RF, Khan MT, and Jothianandan D. 
Federation proceedings 46:385 (1987) 
4-Ignarro L.J., Harbison R.G., Wood K.S., Kadowitz P.J. 
J Pharmacol Exp Ther. 237:893-900. (1986) 
5-Mannick J.B., Schonhoff C.M. 
Free Radic Res. 38:1-7.(2004) 
6- Gaston, B. M., Carver, J., Doctor, A., Palmer, L. A.  
 
 Mol. Interv. 3 , 253–263. (2003) 
 
7- Lima B., Forrester M.T., Hess D.T., Stamler J.S. 
 
Circ Res. 106:633-46. (2010) 
8- Chen K., Popel A.S. 
Biorheology. 46:107-19. (2009) 
9- Foster M.W., Hess D.T., Stamler J.S. 
 
Trends Mol Med. 15:391-404 (2009) 
10- D.P. Ballou, Y. Zhao, P.E. Brandish, M.A. Marletta 
PNAS, 99:19, 12097-12101 (2002) 
 
 168 
11- Lincoln T.M. 
Pharmacol Ther. 41:479-502. (1989) 
12- O'Dell T.J., Hawkins R.D., Kandel E.R., Arancio O. 
Proc Natl Acad Sci U S A. 88:11285-9. (1991) 
13- L.J. Ignarro, J.M. Fukuto, J.M. Griscavage, N.E. Rogers, R.E. Byrns 
       
Proc Natl Acad Sci U S A.  90: 8103–8107 (1993) 
 
14- Kominami S. Yamazaki T., Koga T., Hori H. 
 
J Biochem. 126:756-61. (1999) 
15- Moser, C. C., Keske, J. M., Warncke, K., Farid, R. S., & Dutton, P. L. 
Nature  355, 796-802, (1992) 
16- Buhks E., Jortner J. 
FEBS letters 109:1 (1980) 
17- C. C. Moser, C. C. Page, X. Chen and P. L. Dutton 
 Journal of inorganic biological chemistry, 2;393-398 (1991) 
18- Moser, C. C., Keske, J. M., Warncke, K., Farid, R. S., & Dutton, P. L.  
 Nature  355, 796-802, (1992) 
19- J. N. Betts, D. N. Beratan, J. N. Onuchic, 
J. Am. Chem. Soc. 114; 4043 (1992) 
20- Stuehr D.J. 
Biochim Biophys Acta.; 1411:217-30. (1999) 
21- C. Giroud, M. Moreau, T.A. Mattioli, V. Balland,  J. Boucher, Y. Xu-Li, D.J. Stuehr, 
J. Santolini. 
Journal of Biological Chemistry  285; 7233-7245. (2010) 
 
 169 
22- J. O. Lundberg, E. Weitzberg, M. T. Gladwin 
Nature Reviews Drug Discovery  7; 156-167 (2008) 
23- Cosby K., Partovi K.S., Crawford J.H., Patel R.P., Reiter C.D., Martyr S., Yang B.K., 
Waclawiw M.A., Zalos G., Xu X., Huang K.T., Shields H., Kim-Shapiro D.B., Schechter 
A.N., Cannon R.O., Gladwin M.T. 
Nat Med. 9;1498-505. (2003) 
24- J. O. Lundberg, E. Weitzberg 
Am J Physiol Heart Circ Physiol 295: 477-478 (2008) 
25-  Nagababu, E., Ramasamy, S., Abernethy, D. R. & Rifkind, J. M. 
 
Journal of Biological Chemistry 278; 46349–46356 (2003). 
 
26- Rassaf, T.  
 
Circ. Res. 100; 1749–1754 (2007) 
 
27-  Godber, B. L. 
 
Journal of Biological Chemistry 275, 7757–7763 (2000)  
 
28- Carlsson, S., Wiklund, N. P., Engstrand, L., Weitzberg, E. & Lundberg, J. O.  
 
Nitric Oxide 5, 580–586 (2001) 
 
 
29- Gago, B., Lundberg, J. O., Barbosa, R. M. & Laranjinha, J.  
 
Free Radic. Biol. Med. 43, 1233–1242 (2007) 
 
30- Lundberg, J. O., Weitzberg, E., Lundberg, J. M. & Alving, K.  
 
Gut 35, 1543–1546 (1994) 
 
31- Presta, A., Siddhanta, U., Wu, C., Sennequier, N., Huang, L., Abu-Soud, H.M., 
Erzurum, S., Stuehr, D.J. 
 





32- Spratt, D. E., Newman, E., Mosher, J., Ghosh, D.K., Salerno, J.C., Guillemette, J.G. 
FEBS Journal  273 (2006) 
33- E.D. Garcin, C.M. Bruns, S.J. Lloyd, D.J. Hosfield, M. Tiso, R. Gachhui, D.J. Stuehr, 
J.A. Tainer,  E.D. Getzoff  
Journal of Biological Chemistry 279; 37918–37927 (2004) 
 
34- Zhou, L., Zhu, D. 
 
Nitric Oxide  20;  223-230. (2009) 
35- Garcin, E.D.,  Bruns, C.M.,  Lloyd, S.J.,  Hosfield, D.J.,  Tiso, M.,  Gachhui, R.,  
Stuehr, D.J.,  Tainer, J.A.,  Getzoff, E.D. 
J.Biol.Chem. 279: 37918-37927 (2004) 
36- C.R. Nishida, P.R.O. Montellano 
Journal of Biological Chemistry 274; 14692-14698 (1999) 
37- A. Welland, S. Daff 
FEBS Journal  277; 3833–3834  (2010) 
38- S. Fuziwara, I. Sagami, E. Rozhkova, D. Craig, M.A. Noble, A.W. Munro, S.K. 
Chapman, T. Shimizu 
Journal of Inorganic Biochemistry  91; 515-526 (2002) 
39- K. Knight, N.S. Scrutton 
 
Biochem J. 367; 19–30. (2002) 
 
40- Sagami, I., Sato, Y., Noguchi, T., Miyajima, M., Rozhkova, E., Daff, S. and Shimizu,        
T. 
 
Coord. Chem. Rev. 226, 179-186 (2002) 
41- Abu-Soud H.M., Yoho L.L., Stuehr D.J. 
J Biol Chem 269, 32047–32050. (1994)   
42- Deng Z., Aliverti A., Zanetti G., Arakaki A. K., Ottado J., Orellano E. G., Calcaterra 
N. B., Ceccarelli E. A., Carrillo N., Karplus P. A. 
 
Nat. Struct. Biol. 6:847–853 (1999) 
 171 
 
43- K. Panda, M.M. Haque, E.D.Garcin-Hosfield, D. Durra, E.D. Getzoff, D.J. Stuehr. 
 
Journal of Biological Chemistry 281, 36819-36827. (2006) 
 
44- K. Yamamoto, S. Kimura, Y. Shiro, T. Iyanagi. 
 
Archives of Biochemistry and Biophysics  440; 65-78 (2005) 
 
45- Lowe P.N., Smith D., Stammers D.K., Riveros-Moreno V., Moncada S., Charles I.,                                          
Boyhan A. 
 
Biochem J. 314: 55-62. (1996) 
 
46- H. Kuboniwa, N. Tjandra, S. Grzesiek, H. Ren, C.B. Klee,  A. Bax 
 
Nature Structural Biology  2; 768 - 776 (1995) 
 
47- R.C. Venema, H.S. Sayegh, J.D. Kent, D.G. Harrison 
 
The Journal of Biological Chemistry, 271, 6435-6440 (1996) 
 
48- C. Feng, L. Roman, J. Hazzard, D. Ghosh, G. Tollin, B. Masters 
 
FEBS Letters, 582; 2768-2772 (2008) 
 
49-  Qie Q. W., Cho H., Kashiwabara Y., Baum M., Weidner J. R., Elliston K., Mumford 
R., Nathan C. 
 
Journal of Biological Chemistry 269:28500–28505. (1994) 
 
50- Roman L. J., Miller R. T., de La Garza M. A., Kim J. J.,  Siler Masters B. S. 
 
Journal of Biological Chemistry 275:21914–21919. (2000) 
 
51- Roman L. J., Martasek P., Miller R. T.,  Harris D. E.,  de La Garza M. A.,  Shea T. 
M.,  Kim J. J.,  Masters B. S. 
 
Journal of Biological Chemistry 275:29225–29232. (2000) 
 
52- L.J. Roman, B.S. Masters 
 





53- D.H. Craig, S.K. Chapman, S. Daff 
 
Journal of Biological Chemistry, 277; 33987-33994 (2002) 
 
54- S.L. Delker, H. Ji, H. Li, J. Jamal, J. Fang, F. Xue, R.B. Silverman, T.L. Poulos 
 
J. Am. Chem. Soc. 132; 5437–5442 (2010) 
55- Deng Z., Aliverti A., Zanetti G., Arakaki A. K., Ottado J., Orellano E. G., Calcaterra 
N. B., Ceccarelli E. A., Carrillo N., Karplus P. A. 
 
Nat. Struct. Biol. 6:847–853 (1999) 
 
56- Doukov, T.,   Li, H.,   Soltis, M.,   Poulos, T.L. 
Biochemistry  48; 10246-10254 (2009)  
 
57- McInnes, C.R., Suckling, C.J., Gibson, C.L., Morthala, R., Daff, S., Gazur, B.   
 
Pteridines 20;  27-35 (2009) 
 
58- H.J. Cho, E. Martin, Q. Xie, S. Sassa, C. Nathan 
 
Proc. Natl. Acad. Sci. USA  92; 11514-11518  (1995) 
 
59- K. Pant, B.R. Crane 
 
Journal of Molecular Biology 352; 932-940 (2005) 
60- Davis M.D., Kaufman S., Milstien S. 
Eur J Biochem. 173; 345-51 (1998) 
61- Stoll S., NejatyJahromy Y., Woodward J.J., Ozarowski A., Marletta M.A., Britt R.D. 
J Am Chem Soc. 132:11812-23. (2010) 
62- D.K. Menyhárd 
Chemical Physics Letters 392, 439-443 (2004) 
63- P.F. Fitzpatrick 
 






64- K. Teigen, K.K. Dao, J.A. McKinney, A.C.F. Gorren, B. Mayer, N.Å. Frøystein, J. 
Haavik, A. Martínez 
 
J. Med. Chem. 47 (24), 5962–5971 (2004) 
 
65- Andersen, O.A.,   Stokka, A.J.,   Flatmark, T.,   Hough, E. 
J.Mol.Biol. 333: 747-757 (2003) 
 
66- Bigham E.C., Smith G.K., Reinhard J.F., Mallory W.R., Nichol C.A., Morrison R.W. 
 
J Med Chem.;30(1):40-5. (1987) 
 
67- United States Patent 5874433 
 
68- Frantom P.A., Seravalli J., Ragsdale S.W., Fitzpatrick P.F.  
 
Biochemistry. 45: 2372-9. (2006) 
69- P.R.O. Montellano, J. J. De Voss  
Nat. Prod. Rep., 19, 477–493 (2002) 
 
70- Paul R. Ortiz de Montellano 
 
Cytochrome P450: structure, mechanism, and biochemistry (available online) 
71- Sono M., Roach M.P., Coulter E.D., Dawson J.H. 
Chem Rev. 96: 2841-2888. (1996) 
72- S. Modi, M.J. Sutcliffe, W.U. Primrose, L. Lian, G.C.K. Roberts 
Nature Structural Biology  3; 414 - 417 (1996) 
73- M. Newcomb, R. Zhang, R. E.P. Chandrasena, J.A. Halgrimson, J.H. Horner, T.M. 
Makris, S.G. Sligar 
 
J Am Chem Soc. 128; 4580–4588 (2006) 
 
74- J. Rittle, M.T. Green 
 
Science 330; 933-937 (2010) 
 
75- Ogliaro, F., Harris, N., Cohen, S., Filatov, M., Visser, S.P. de, Shaik, S. 
 
J. Am. Chem. Soc., 122, 8977-8989  (2000) 
 174 
 
76- R. Davydov, T.M. Makris, V. Kofman, D.E. Werst, S.G. Sligar, B.M. Hoffman 
J. Am. Chem. Soc., 123; 1403–1415 (2001) 
77- D. Hamdane, H. Zhang, P. Hollenberg 
 
Photosynth Res., 98; 657–666. (2008)  
 
78- A. Presta, A.M. Weber-Main, M.T. Stankovich, D.J. Stuehr 
 
J. Am. Chem. Soc., 120; 9460–9465 (1998) 
 
79- Abu-Soud H.M., Ichimori K., Presta A., Stuehr D.J. 
 
J Biol Chem. 275; 17349-57. (2000) 
 
80- Gao Y.T., Panda S.P., Roman L.J., Martásek P., Ishimura Y., Masters B.S. 
 
J Biol Chem. 282; 7921-9. (2007) 
 
81- R. Davydov, R. Kappl, J. Hüttermann, J. A. Peterson 
 
FEBS letters 295; 113-115 (1991) 
82- Hurshman A.R., Krebs C., Edmondson D.E., Huynh B.H., Marletta M.A. 
Biochemistry. 38; 15689-96. (1999) 
83- Ost T.W., Daff S. 
J Biol Chem. 280; 965-73. (2005) 
84-Wei C.C., Wang Z.Q., Tejero J., Yang Y.P., Hemann C., Hille R., Stuehr D.J. 
J Biol Chem. 283; 11734-42. (2008) 
85- Woodward J.J., Chang M.M., Martin N.I., Marletta M.A. 
J Am Chem Soc. 131; 297-305. (2009) 
86- R. Davydov, A. Ledbetter-Rogers, P. Martásek, M. Larukhin, M. Sono, J.H. Dawson, 
B.S. Masters, B.M. Hoffman 
Biochemistry, 41; 10375–10381 (2002) 
 175 
87- Goloubinoff, P., Gatenby, A.A and Lorimer, G.H. 
J. Inher. Metab. Dis. 17; 661–663. (1989) 
 
88- R.A. Pufahl, J.S. Wishnok, M.A. Marletta 
 
Biochemistry, 34; 1930–1941 (1995) 
 
89- V. M. Ivanov 
 
J. of analytical chemistry. 59; 1002-1005, (1979) 
 
90- Sorlie M., Gorren A.C., Marchal S., Shimizu T., Lange R., Andersson K.K., May G. 
 
J Biol Chem. 278; 48602-10. (2003) 
 
91- H.M. Abu-Soud, A. Presta, B. Mayer, D.J. Stuehr 
 
Biochemistry, 36; 10811–10816 (1997) 
 
92- Robinet, J. J., Cho, K-B. and Gauld, J. W 
 
J. Am. Chem. Soc. 130; 3328-3334. (2008) 
 
93- Martin, N.I., Woodward, J.J., Winter, M.B., Marletta, M.A. 
 
Bioorganic & Medicinal Chemistry Letters  19;  1758-1762. (2009)   
 
94- Vidakovic M., Sligar S.G., Li H., Poulos T.L. 
 
Biochemistry. 37; 9211-9. (1998) 
 
95- Tejero, J., Biswas, A., Wang, Z., Page, R.C., Haque, M.M., Hemann, C., Zweier, J.L., 
Misra, S., Stuehr, D.J. 
 
Journal of Biological Chemistry   283; 33498-33507 (2008) 
 
96- C.T. Migita, J.C. Salerno, B.S. Masters, P. Martasek, K. McMillan, M. Ikeda-Saito 
Biochemistry 36: 10987-92. (1997) 
97- Sliger, S.G. 
Science 330; 924-925 (2010) 
 
 176 
98- M. J. Clague, J. S. Wishnok, M. A. Marletta 
 
Biochemistry, 36, 14465–14473 (1997) 
99- S. Daff 
Nitric Oxide  23;  1-11.  (2010) 
 
100- Gorren A.C., Mayer B. 
Biochim Biophys Acta. 1770; 432-45. (2007) 
101- I.G. Denisov, J.H. Dawson, L.P. Hager, S.G. Sligar 
Biochem Biophys Res Commun. 363; 954–958. (2007) 
 
102- S.R. Bell, J.T. Groves 
 
J. Am. Chem. Soc., 131;  9640–9641 (2009) 
 
103- Spolitak, T., Dawson, J. H. and Ballou, D. P. 
Journal of Biological Chemistry 280, 20300-20309. (2005) 
104- Sheng, X., Homer, J. H. and Newcomb, M. 
J. Am. Chem. Soc. 130; 13310-13320. (2008) 
105- H.L. Voegtle, M. Sono, S. Adak, A.E. Pond, T. Tomita, R. Perera, D.B. Goodin, 
M. Ikeda-Saito, D.J. Stuehr, J.H. Dawson 
 
Biochemistry, 42; 2475-2484 (2003) 
 
106- De Visser, S. P. and Tan, L. S. 
 
J. Am. Chem. Soc. 130, 12961-12974 (2008) 
107- Abu-Soud H.M., Wu C., Ghosh D.K., Stuehr D.J. 
Biochemistry. 37; 3777-86. (1998) 
108- H.M. Abu-Soud, J. Wang, D.L. Rousseau, J.M. Fukuto, L.J. Ignarro, D.J. Stuehr 
Journal of biological chemistry  270; 22997–23006 (1995) 
 
 177 
109- V. M. Ivanov 
J. of analytical chemistry. 59; 1002-1005 (1995) 
110- J. Tejero, J. Santolini, D.J. Stuehr 
 
FEBS J.  276; 4505–4514. (2009) 
 
111- C. Wei, Z. Wang, Q. Wang, A.L. Meade, C. Hemann, R. Hille, D.J. Stuehr 
  
Journal of biological chemistry  276; 315–319, (2001) 
 
112- Ayling J.E., Bailey S.W., Boerth S.R., Giugliani R., Braegger C.P., Thöny B., Blau 
N. 
 
Mol Genet Metab. 70; 179-88. (2000) 
 
113- W. Shi, C.J. Meininger, T.E. Haynes, K. Hatakeyama, G. Wu 
 
Cell biochemistry and biophysics,  41; 415-433, (2006) 
 
114- C.O. Harding 
 
Biologics. 4; 231–236. (2010) 
 
115- E. Podjarny, G. Hasdan, J. Bernheim, G. Rashid, J. Green, Z. Korzets, J. 
Bernheim 
Nephrology Dialysis Transplantation 19;  2223-2227. (2005) 
 
116- Gorren A.C., Sørlie M., Andersson K.K., Marchal S., Lange R., Mayer B. 
 
Methods Enzymol. 396; 456-66. (2005) 
 
117- Suckling C.J., Gibson C.L., Huggan J.K., Morthala R.R., Clarke B., Kununthur S., 
Wadsworth R.M., Daff S., Papale D. 
Bioorg Med Chem Lett.;18(5):1563-6. (2008). 




119- M.L. Dántola, A.H. Thomas, E. Oliveros, C. Lorente  
 
Journal of Photochemistry and Photobiology A: Chemistry  209; 104-110 (2010) 
120- K. Panda, S. Ghosh, D.J. Stuehr  
Journal of biological chemistry  276; 23349 –23356 (2001) 
121- C.R. Nishida, P.R.O. de Montellano 
 Journal of biological chemistry  273; 5566 –5571, (1998) 
122- U. Siddhanta, A. Presta, B. Fan, D. Wolan, D.L. Rousseau, D.J. Stuehr 
 

















Appendix 1: nNOS sequence 
 
 
From Rattus norvergicus 
 
 
Amino acid sequence 
 
        10 20  30    40     50       60 
MEENTFGVQQ IQPNVISVRL FKRKVGGLGF LVKERVSKPP VIISDLIRGG AAEQSGLIQA  
        70         80         90        100        110        120  
GDIILAVNDR PLVDLSYDSA LEVLRGIASE THVVLILRGP EGFTTHLETT FTGDGTPKTI  
       130        140        150        160        170        180  
RVTQPLGPPT KAVDLSHQPS ASKDQSLAVD RVTGLGNGPQ HAQGHGQGAG SVSQANGVAI  
       190        200        210        220        230        240  
DPTMKSTKAN LQDIGEHDEL LKEIEPVLSI LNSGSKATNR GGPAKAEMKD TGIQVDRDLD  
       250        260        270        280        290        300  
GKSHKAPPLG GDNDRVFNDL WGKDNVPVIL NNPYSEKEQS PTSGKQSPTK NGSPSRCPRF  
       310        320        330        340        350        360 
LKVKNWETDV VLTDTLHLKS TLETGCTEHI CMGSIMLPSQ HTRKPEDVRT KDQLFPLAKE  
       370        380        390        400        410        420  
FLDQYYSSIK RFGSKAHMDR LEEVNKEIES TSTYQLKDTE LIYGAKHAWR NASRCVGRIQ  
       430        440        450        460        470        480  
WSKLQVFDAR DCTTAHGMFN YICNHVKYAT NKGNLRSAIT IFPQRTDGKH DFRVWNSQLI  
       490        500        510        520        530        540  
RYAGYKQPDG STLGDPANVQ FTEICIQQGW KAPRGRFDVL PLLLQANGND PELFQIPPEL  
       550        560        570        580        590        600  
VLEVPIRHPK FDWFKDLGLK WYGLPAVSNM LLEIGGLEFS ACPFSGWYMG TEIGVRDYCD  
       610        620        630        640        650        660  
NSRYNILEEV AKKMDLDMRK TSSLWKDQAL VEINIAVLYS FQSDKVTIVD HHSATESFIK  
       670        680        690        700        710        720  
HMENEYRCRG GCPADWVWIV PPMSGSITPV FHQEMLNYRL TPSFEYQPDP WNTHVWKGTN  
       730        740        750        760        770        780  
GTPTKRRAIG FKKLAEAVKF SAKLMGQAMA KRVKATILYA TETGKSQAYA KTLCEIFKHA  
       790        800        810        820        830        840  
FDAKAMSMEE YDIVHLEHEA LVLVVTSTFG NGDPPENGEK FGCALMEMRH PNSVQEERKS  
       850        860        870        880        890        900  
YKVRFNSVSS YSDSRKSSGD GPDLRDNFES TGPLANVRFS VFGLGSRAYP HFCAFGHAVD  
       910        920        930        940        950        960  
TLLEELGGER ILKMREGDEL CGQEEAFRTW AKKVFKAACD VFCVGDDVNI EKPNNSLISN  
       970        980        990       1000       1010       1020  
 180 
DRSWKRNKFR LTYVAEAPDL TQGLSNVHKK RVSAARLLSR QNLQSPKFSR STIFVRLHTN  
      1030       1040       1050       1060       1070       1080  
GNQELQYQPG DHLGVFPGNH EDLVNALIER LEDAPPANHV VKVEMLEERN TALGVISNWK  
      1090       1100       1110       1120       1130       1140  
DESRLPPCTI FQAFKYYLDI TTPPTPLQLQ QFASLATNEK EKQRLLVLSK GLQEYEEWKW  
      1150       1160       1170       1180       1190       1200  
GKNPTMVEVL EEFPSIQMPA TLLLTQLSLL QPRYYSISSS PDMYPDEVHL TVAIVSYHTR  
      1210       1220       1230       1240       1250       1260  
DGEGPVHHGV CSSWLNRIQA DDVVPCFVRG APSFHLPRNP QVPCILVGPG TGIAPFRSFW  
      1270       1280       1290       1300       1310       1320  
QQRQFDIQHK GMNPCPMVLV FGCRQSKIDH IYREETLQAK NKGVFRELYT AYSREPDRPK  
      1330       1340       1350       1360       1370       1380  
KYVQDVLQEQ LAESVYRALK EQGGHIYVCG DVTMAADVLK AIQRIMTQQG KLSEEDAGVF  
      1390       1400       1410       1420   

































1 atggaagaga acacgtttgg ggttcagcag atccaaccca atgtaatttc 
51 tgttcgtctc ttcaaacgca aagtgggagg tctgggcttc ctggtgaagg 
101 aacgggtcag caagcctccc gtgatcatct cagacctgat tcgaggaggt 
151 gctgcggagc agagcggcct tatccaagct ggagacatca ttctcgcagt 
201 caacgatcgg cccttggtag acctcagcta tgacagtgcc ctggaggttc 
251 tcaggggcat tgcctctgag acccacgtgg tcctcattct gaggggccct 
301 gagggcttca ctacacatct ggagaccacc ttcacagggg atggaacccc 
351 caagaccatc cgggtgaccc agcccctcgg tcctcccacc aaagccgtcg 
401 atctgtctca ccagccttca gccagcaaag accagtcatt agcagtagac 
451 agagtcacag gtctgggtaa tggccctcag catgcccaag gccatgggca 
501 gggagctggc tcagtctccc aagctaatgg tgtggccatt gaccccacga 
551 tgaaaagcac caaggccaac ctccaggaca tcggggaaca tgatgaactg 
601 ctcaaagaga tagaacctgt gctgagcatc ctcaacagtg ggagcaaagc 
651 caccaacaga gggggaccag ccaaagcaga gatgaaagac acaggaatcc 
701 aggtggacag agacctcgat ggcaaatcgc acaaagctcc gcccctgggc 
751 ggggacaatg accgcgtctt caatgacctg tgggggaagg acaacgttcc 
801 tgtggtcctt aacaacccgt attcagagaa ggaacagtcc cctacctcgg 
851 ggaaacagtc tcccaccaag aacggcagcc cttccaggtg cccccgtttc 
901 ctcaaggtca agaactggga gacggacgtg gtcctcaccg acaccctgca 
951 cctgaagagc acactggaaa cggggtgcac agagcacatt tgcatgggct 
1001 cgatcatgct gccttcccag cacacgcgga agccagaaga tgtccgcaca 
1051 aaggaccagc tcttccctct agccaaagaa tttctcgacc aatactactc 
1101 atccattaag agatttggct ccaaggccca catggacagg ctggaggagg 
1151 tgaacaagga gattgaaagc accagcacct accagctcaa ggacaccgag 
1201 ctcatctatg gcgccaagca tgcctggcgg aacgcctctc gatgtgtggg 
1251 caggatccag tggtccaagc tgcaggtgtt cgatgcccga gactgcacca 
1301 cagcccacgg catgttcaac tacatctgta accatgtcaa gtatgccacc 
1351 aacaaaggga atctcaggtc ggccatcacg atattccctc agaggactga 
1401 cggcaaacat gacttccgag tgtggaactc gcagctcatc cgctacgcgg 
1451 gctacaagca gccagatggc tctaccttgg gggatccagc caatgtgcag 
1501 ttcacggaga tctgtataca gcagggctgg aaagccccaa gaggccgctt 
1551 cgacgtgctg cctctcctgc ttcaggccaa tggcaatgac cctgagctct 
1601 tccagatccc cccagagctg gtgctggaag tgcccatcag gcaccccaag 
1651 ttcgactggt ttaaggacct ggggctcaaa tggtatggcc tccccgctgt 
1701 gtccaacatg ctgctggaga tcgggggcct ggagttcagc gcctgtccct 
1751 tcagcggctg gtacatgggc acagagatcg gcgtccgtga ctactgtgac 
1801 aactctcgat acaacatcct ggaggaagta gccaagaaga tggatttgga 
1851 catgaggaag acctcgtccc tctggaagga ccaagcactg gtggagatca 
1901 acattgctgt tctatatagc ttccagagtg acaaggtgac catcgttgac 
1951 caccactctg ccacggagtc cttcatcaaa cacatggaga atgaataccg 
2001 ctgcagaggg ggctgccccg ccgactgggt gtggattgtg cctcccatgt 
2051 cgggcagcat cacccctgtc ttccaccagg agatgctcaa ctatagactc 
2101 accccgtcct ttgaatacca gcctgatcca tggaacaccc acgtgtggaa 
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2151 gggcaccaac gggaccccca cgaagcggcg agctatcggc tttaagaaat 
2201 tggcagaggc cgtcaagttc tcagccaagc taatggggca ggccatggcc 
2251 aagagggtca aggcgaccat tctctacgcc acagagacag gcaaatcaca 
2301 agcctatgcc aagaccctgt gtgagatctt caagcacgcc ttcgatgcca 
2351 aggcaatgtc catggaggag tatgacatcg tgcacctgga gcacgaagcc 
2401 ctggtcttgg tggtcaccag cacctttggc aatggagacc cccctgagaa 
2451 cggggagaaa ttcggctgtg ctttaatgga gatgaggcac cccaactctg 
2501 tgcaggagga gagaaagagc tacaaggtcc gattcaacag cgtctcctcc 
2551 tattctgact cccgaaagtc atcgggcgac ggacccgacc tcagagacaa 
2601 ctttgaaagt actggacccc tggccaatgt gaggttctca gtgttcggcc 
2651 tcggctctcg ggcgtacccc cacttctgtg cctttgggca tgcggtggac 
2701 accctcctgg aggaactggg aggggagagg attctgaaga tgagggaggg 
2751 ggatgagctt tgcggacagg aagaagcttt caggacctgg gccaagaaag 
2801 tcttcaaggc agcctgtgat gtgttctgcg tgggggatga cgtcaacatc 
2851 gagaaggcga acaactccct cattagcaat gaccgaagct ggaagaggaa 
2901 caagttccgc ctcacgtatg tggcggaagc tccagatctg acccaaggtc 
2951 tttccaatgt tcacaaaaaa cgagtctcgg ctgctcgact cctcagccgc 
3001 caaaacctgc aaagccctaa gtccagccga tcgaccatct tcgtgcgtct 
3051 ccacaccaac gggaatcagg agctgcagta ccagccaggg gaccacctgg 
3101 gtgtcttccc cggcaaccac gaggacctcg tgaatgcact cattgaacgg 
3151 ctggaggatg caccgcctgc caaccacgtg gtgaaggtgg agatgctgga 
3201 ggagaggaac actgctctgg gtgtcatcag taattggaag gatgaatctc 
3251 gcctcccacc ctgcaccatc ttccaggcct tcaagtacta cctggacatc 
3301 accacgccgc ccacgcccct gcagctgcag cagttcgcct ctctggccac 
3351 taatgagaaa gagaagcagc ggttgctggt cctcagcaag gggctccagg 
3401 aatatgagga gtggaagtgg ggcaagaacc ccacaatggt ggaggtgctg 
3451 gaggagttcc cgtccatcca gatgccggct acacttctcc tcactcagct 
3501 gtcgctgctg cagcctcgct actactccat cagctcctct ccagacatgt 
3551 accccgacga ggtgcacctc actgtggcca tcgtctccta ccacacccga 
3601 gacggagaag gaccagtcca ccacggggtg tgctcctcct ggctcaacag 
3651 aatacaggct gacgatgtag tcccctgctt cgtgagaggt gcccctagct 
3701 tccacctgcc tcgaaacccc caggtgcctt gcatcctggt tggcccaggc 
3751 actggcatcg cacccttccg aagcttctgg caacagcgac aatttgacat 
3801 ccaacacaaa ggaatgaatc cgtgccccat ggttctggtc ttcgggtgtc 
3851 gacaatccaa gatagatcat atctacagag aggagaccct gcaggccaag 
3901 aacaagggcg tcttcagaga gctgtacact gcctattccc gggaaccgga 
3951 caggccaaag aaatatgtac aggacgtgct gcaggaacag ctggctgagt 
4001 ctgtgtaccg cgccctgaag gagcaaggag gccacattta tgtctgtggg 
4051 gacgttacca tggccgccga tgtcctcaaa gccatccagc gcataatgac 
4101 ccagcagggg aaactctcag aggaggacgc tggtgtattc atcagcaggc 
4151 tgagggatga caaccggtac cacgaggaca tctttggagt caccctcaga 
4201 acgtatgaag tgaccaaccg ccttagatct gagtccatcg ccttcatcga 
4251 agagagcaaa aaagacgcag atgaggtttt cagctcctaa 
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